



 **SECTION A**

INCIDENCE OF
REPORTED ESRD

A



CONTENTS

- 275 A.1 Incident Counts of Reported ESRD Patients
by demographic characteristics & primary diagnosis
- 276 A.2 Incident Rates of Reported ESRD
per million population, by demographic characteristics & primary diagnosis, unadjusted
- 277 A.3 Incident Rates of Reported ESRD
per million population, by demographic characteristics & primary diagnosis, adjusted for age, gender, ethnicity, & race
- 278 A.4 Incident Counts of Reported ESRD Patients: by Time Period
grouped by age, gender, & race
- 279 A.5 Incident Rates of Reported ESRD: by Time Period
per million population, adjusted for & grouped by age, gender, & race
- 280 A.6 Incident Counts of Reported ESRD Patients: by Primary Diagnosis
1996-1999, grouped by age, gender, & race
- 282 A.7 Incident Rates of Reported ESRD: by Primary Diagnosis
1996-1999, per ten million population, adjusted for & grouped by age, gender, & race
- 285 A.8 Mean Age at Start of ESRD Therapy
by demographic characteristics & primary diagnosis
- 286 A.9 Incidence of Reported ESRD: All Patients, by Detailed Primary Diagnosis
1995-1999, row percent
- 287 A.10 Incidence of Reported ESRD: All Patients, by Detailed Primary Diagnosis
1995-1999, column percent
- 288 A.11 Incidence of Reported ESRD: Hispanics, by Detailed Primary Diagnosis
1995-1999, row percent
- 289 A.12 Incidence of Reported ESRD: Hispanics, by Detailed Primary Diagnosis
1995-1999, column percent
- 290 A.13 Incidence of Reported ESRD: Non-Hispanics, by Detailed Primary Diagnosis
1995-1999, row percent
- 291 A.14 Incidence of Reported ESRD: Non-Hispanics, by Detailed Primary Diagnosis
1995-1999, column percent
- 292 A.15 Incident Counts of Reported ESRD Patients: by Diabetic Status & State
after dropping patients in the U.S. Territories & in states designated as "unknown"
- 295 A.16 Incident Rates of Reported ESRD: by Diabetic Status & State
per million population, adjusted for age, gender, & race
- 298 A.17 Incident Counts of Reported ESRD Patients: by Diabetic Status & Network
after dropping patients in the U.S. Territories & in states designated as "unknown"
- 299 A.18 Incident Rates of Reported ESRD: by Diabetic Status & Network
per million population, adjusted for age, gender, & race

A

Table A.1
Incident Counts of Reported ESRD Patients
by demographic characteristics & primary diagnosis

	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	142	172	158	175	168	187	204	193	191	195
5-9	158	135	120	139	172	157	152	146	145	170
10-14	246	238	231	244	265	287	285	290	280	317
15-19	528	462	494	526	564	572	597	543	552	610
20-24	899	922	1,002	979	1,093	1,054	1,034	963	1,023	936
25-29	1,538	1,559	1,567	1,651	1,932	1,668	1,670	1,689	1,725	1,669
30-34	2,077	2,142	2,229	2,313	2,768	2,551	2,457	2,407	2,457	2,419
35-39	2,425	2,603	2,859	2,838	3,628	3,371	3,345	3,348	3,357	3,428
40-44	2,844	3,175	3,382	3,381	4,090	4,149	4,310	4,260	4,562	4,554
45-49	2,888	3,313	3,644	3,949	4,946	4,995	5,270	5,387	5,816	5,991
50-54	3,376	3,610	4,159	4,365	5,693	5,553	5,707	6,299	6,875	7,387
55-59	4,296	4,655	5,061	5,236	6,659	6,546	6,731	7,306	7,901	8,297
60-64	5,614	6,257	6,582	6,800	8,112	8,197	8,314	8,835	9,324	9,339
65-69	7,019	7,877	8,448	8,745	9,821	9,415	9,795	10,714	10,753	10,682
70-74	6,008	7,203	7,992	8,411	9,610	9,462	10,183	11,275	11,350	11,489
75-79	4,456	5,348	5,933	6,211	7,211	7,268	8,023	9,299	9,932	10,662
80-84	2,330	2,738	3,206	3,382	4,010	4,202	4,733	5,735	6,031	6,487
85+	931	1,101	1,263	1,464	1,645	1,809	2,135	2,623	3,069	3,459
Male	25,830	28,683	30,912	32,397	37,898	37,605	40,027	43,157	45,272	46,986
Female	21,945	24,827	27,418	28,412	34,489	33,838	34,918	38,155	40,071	41,105
White	31,169	34,779	37,505	38,252	43,791	43,740	45,639	51,643	53,752	56,525
Black	14,350	16,151	17,679	18,805	22,055	22,520	23,675	24,374	25,785	25,937
Native American	651	724	876	832	993	1,180	1,328	959	1,385	1,090
Asian	1,227	1,365	1,567	1,815	2,298	2,488	2,649	2,611	2,952	2,970
Other/unknown	378	491	703	1,105	3,250	1,515	1,654	1,725	1,469	1,569
Hispanic	1,611	1,969	2,417	2,960	3,143	6,535	7,872	8,076	8,872	9,009
Non-Hispanic	46,164	51,541	55,913	57,849	69,244	64,908	67,073	73,236	76,471	79,082
Diabetes	16,093	18,890	20,940	21,006	25,594	28,464	31,560	34,925	36,941	38,160
Hypertension	13,762	15,775	17,554	16,819	20,229	18,131	19,189	21,260	22,316	23,133
Glomerulonephritis	5,840	6,168	6,448	6,389	7,347	7,554	8,011	8,100	8,243	8,038
Cystic kidney	1,424	1,507	1,602	1,551	1,762	1,850	1,826	1,933	2,104	2,096
Other urologic	817	1,118	1,158	1,034	1,169	1,306	1,502	1,476	1,525	1,590
Other cause	4,733	4,965	5,273	5,221	6,351	7,905	8,341	8,909	9,415	9,675
Unknown cause	1,947	2,355	2,611	2,323	2,625	2,609	2,939	3,145	3,408	3,356
Missing disease	3,159	2,732	2,744	6,466	7,310	3,624	1,577	1,564	1,391	2,043
U.S.	47,150	52,870	57,429	59,437	67,265	70,978	74,763	81,149	85,145	87,794
Presumed U.S.	625	640	901	1,372	5,122	465	182	163	198	297
Puerto Rico	552	629	730	687	851	851	950	973	1,045	1,109
Other non-U.S.	23	26	37	22	33	41	49	56	50	52
All	48,350	54,165	59,097	61,518	73,271	72,335	75,944	82,341	86,438	89,252

On our website: incident patient counts by race and primary diagnosis (Tables A.3.1-A.3.12); patients residing in Puerto Rico and the Territories (Table A.a); incident counts after dropping "other" and "unknown" races (Table A.b); & patients of "other" and "unknown" race (Table A.c).

Table A.2

Incident Rates of Reported ESRD*per million population, by demographic characteristics & primary diagnosis, unadjusted*

	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	7	9	8	9	8	9	10	9	9	10
5-9	9	7	6	7	9	8	7	7	7	8
10-14	14	13	12	12	13	15	14	14	14	16
15-19	29	26	28	28	30	30	30	26	27	30
20-24	46	47	51	50	54	56	56	52	55	49
25-29	71	74	76	81	92	85	85	86	89	88
30-34	93	95	98	101	114	113	111	113	118	118
35-39	120	125	133	127	150	147	144	144	145	148
40-44	157	167	176	171	191	200	200	194	204	199
45-49	206	232	233	242	277	279	278	283	302	303
50-54	293	306	338	334	405	395	399	403	427	437
55-59	407	440	475	477	573	575	575	605	623	630
60-64	526	587	624	652	770	798	810	857	890	870
65-69	695	782	842	864	961	931	974	1,076	1,106	1,116
70-74	747	871	938	968	1,083	1,061	1,145	1,272	1,278	1,298
75-79	724	851	924	952	1,079	1,073	1,151	1,301	1,365	1,444
80-84	591	677	773	788	907	928	1,026	1,222	1,269	1,339
85+	304	344	379	422	453	484	557	664	755	822
0-19	14	14	13	14	14	15	15	14	14	16
20-44	96	101	107	107	122	122	122	121	126	125
45-64	346	377	396	401	472	472	471	488	511	512
65-74	718	822	886	912	1,018	992	1,054	1,169	1,188	1,204
75+	586	679	748	774	873	883	966	1,118	1,182	1,254
Male	211	231	246	253	285	287	303	323	337	346
Female	170	190	207	211	247	246	251	272	285	290
White	149	165	176	178	202	201	208	233	241	252
Black	469	519	558	584	675	680	706	717	749	744
Other	195	208	233	243	292	314	330	286	338	307
Hispanic						209	244	240	266	260
Non-Hispanic						273	280	304	316	325
Diabetes	64	75	81	81	97	106	116	127	135	138
Hypertension	55	62	68	65	76	68	71	78	82	84
Glomerulonephritis	23	24	25	24	28	28	29	29	30	29
Cystic kidney	6	6	6	6	7	7	7	7	8	8
Other urologic	3	4	4	4	4	5	6	5	6	6
Other cause	19	20	21	20	24	30	31	33	34	35
Unknown cause	8	9	10	9	10	10	11	11	12	12
Missing disease	12	10	10	23	20	13	5	5	5	7
Crude rate	190	210	226	232	266	266	276	297	310	317

Table A.3

Incident Rates of Reported ESRD*per million population, by demographic characteristics & primary diagnosis, adjusted for age, gender, ethnicity, & race*

	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	7	9	8	8	7	8	9	9	9	10
5-9	8	7	6	7	8	8	7	7	6	8
10-14	14	13	12	12	13	14	14	14	13	15
15-19	28	25	27	27	28	29	29	25	25	29
20-24	45	45	49	48	52	53	53	49	53	47
25-29	71	73	75	79	90	82	83	84	86	84
30-34	94	95	99	101	114	112	110	111	115	116
35-39	123	127	135	129	152	148	145	144	144	147
40-44	167	176	183	178	198	206	206	198	208	201
45-49	223	251	254	264	300	301	297	298	316	315
50-54	316	330	365	364	442	433	436	441	465	473
55-59	446	481	518	521	625	624	627	652	679	685
60-64	589	651	693	720	842	875	882	927	965	938
65-69	788	883	944	975	1,067	1,025	1,074	1,166	1,196	1,198
70-74	857	990	1,068	1,117	1,237	1,217	1,310	1,430	1,440	1,437
75-79	856	998	1,082	1,114	1,269	1,259	1,360	1,485	1,569	1,641
80-84	739	851	962	987	1,111	1,135	1,277	1,466	1,529	1,593
85+	430	493	526	568	615	650	779	874	996	1,067
0-19	14	14	13	14	14	15	15	14	13	15
20-44	100	103	108	107	121	120	119	117	121	119
45-64	393	428	458	467	552	558	561	580	607	603
65-74	823	936	1,006	1,046	1,152	1,121	1,192	1,298	1,318	1,317
75+	675	781	857	890	999	1,015	1,138	1,275	1,365	1,434
Male	244	266	282	289	323	322	339	360	372	380
Female	165	183	198	201	234	233	236	253	263	266
White	147	161	172	173	196	193	199	222	229	237
Black	624	694	745	779	888	885	922	934	968	953
Native American	501	546	655	603	679	784	862	609	865	652
Asian	241	256	277	304	366	388	397	371	400	386
Hispanic						352	414	404	448	433
Non-Hispanic						266	272	293	302	308
Diabetes	67	78	84	83	99	109	118	129	135	136
Hypertension	59	66	72	67	79	70	73	79	82	83
Glomerulonephritis	24	25	26	25	28	29	30	30	30	29
Cystic kidney	6	6	7	6	7	7	7	7	8	7
Other urologic	3	5	5	4	5	5	6	5	6	6
Other cause	19	20	21	20	24	30	31	33	34	35
Unknown cause	8	10	11	9	10	10	11	12	12	12
Missing disease	12	10	10	24	21	13	5	5	5	7
Crude rate	190	210	226	232	266	266	276	297	310	317
Adjusted rate	199	220	235	239	273	272	281	300	310	315

Table A.4

Incident Counts of Reported ESRD Patients: by Time Period*grouped by age, gender, & race*

1994-1996	Males					Females					Both genders				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-4	214	71	*	*	295	148	46	*	10	207	362	117	*	17	502
5-9	195	64	*	12	274	134	35	*	*	178	329	99	*	15	452
10-14	269	140	*	15	431	227	102	*	19	354	496	242	13	34	785
15-19	543	369	12	35	959	406	235	12	32	685	949	604	24	67	1,644
20-29	2,253	1,927	54	140	4,374	1,834	1,546	63	155	3,598	4,087	3,473	117	295	7,972
30-39	5,229	4,448	157	281	10,115	3,561	3,099	124	290	7,074	8,790	7,547	281	571	17,189
40-49	8,050	6,613	348	478	15,489	5,711	4,639	283	462	11,095	13,761	11,252	631	940	26,584
50-59	11,066	6,636	400	716	18,818	8,831	6,756	449	596	16,632	19,897	13,392	849	1,312	35,450
60-64	7,780	3,509	183	402	11,874	6,902	4,446	258	399	12,005	14,682	7,955	441	801	23,879
65-69	10,137	3,193	185	499	14,014	8,907	4,732	278	526	14,443	19,044	7,925	463	1,025	28,457
70-79	20,594	4,646	210	850	26,300	16,439	7,163	329	892	24,823	37,033	11,809	539	1,742	51,123
80+	7,456	1,439	45	321	9,261	6,284	2,396	83	295	9,058	13,740	3,835	128	616	18,319
All	73,786	33,055	1,607	3,756	112,204	59,384	35,195	1,894	3,679	100,152	133,170	68,250	3,501	7,435	212,356
1997-1999															
0-4	236	68	.	*	312	154	53	*	*	217	390	121	*	15	529
5-9	163	49	*	*	219	142	52	*	*	204	305	101	*	12	423
10-14	315	96	*	10	429	258	130	*	21	411	573	226	10	31	840
15-19	508	294	*	26	835	466	265	*	41	781	974	559	16	67	1,616
20-29	2,234	1,691	35	185	4,145	1,773	1,520	52	163	3,508	4,007	3,211	87	348	7,653
30-39	5,299	4,159	110	301	9,869	3,542	3,130	94	272	7,038	8,841	7,289	204	573	16,907
40-49	9,368	7,296	302	481	17,447	6,376	5,316	260	453	12,405	15,744	12,612	562	934	29,852
50-59	14,038	7,949	483	771	23,241	11,038	7,542	447	676	19,703	25,076	15,491	930	1,447	42,944
60-64	8,955	3,908	211	463	13,537	7,714	4,886	289	475	13,364	16,669	8,794	500	938	26,901
65-69	11,581	3,680	151	539	15,951	9,770	5,125	261	565	15,721	21,351	8,805	412	1,104	31,672
70-79	26,128	5,481	233	1,079	32,921	20,776	8,291	336	1,084	30,487	46,904	13,772	569	2,163	63,408
80+	11,592	1,840	51	460	13,943	9,494	3,275	85	441	13,295	21,086	5,115	136	901	27,238
All	90,417	36,511	1,593	4,328	132,849	71,503	39,585	1,841	4,205	117,134	161,920	76,096	3,434	8,533	249,983

*Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

Table A.5

Incident Rates of Reported ESRD: by Time Period*per million population, adjusted for & grouped by age, gender, & race***1994-1996**

	Specific Rates (Unadjusted)								Rates Adjusted for:							
	Males				Females				Gender				Race		Gender & Race	
	White	Black	N Am	Asian	White	Black	N Am	Asian	White	Black	N Am	Asian	Male	Female		
0-4	*	15	*	*	*	10	*	*	*	13	*	*	*	*	*	
5-9	*	14	*	11	*	*	18	*	*	11	14	*	*	*	*	
10-14	12	32	20	13	10	24	17	17	11	28	18	15	14	12	13	
15-19	24	86	39	33	19	56	40	31	22	71	39	32	33	25	28	
20-29	50	252	94	60	42	191	116	63	45	221	106	62	76	62	69	
30-39	95	564	288	114	66	347	225	108	80	453	257	111	157	104	130	
40-49	169	1,124	846	245	119	673	650	209	145	914	769	232	305	201	251	
50-59	356	1,980	1,673	643	271	1,610	1,720	482	318	1,817	1,742	576	595	471	531	
60-64	626	2,752	2,252	1,078	504	2,626	2,778	849	563	2,687	2,520	961	928	807	866	
65-69	846	2,708	2,881	1,683	627	2,991	3,623	1,273	734	2,853	3,258	1,473	1,134	979	1,056	
70-79	1,159	3,236	2,557	2,207	684	3,250	3,048	1,758	920	3,230	2,800	2,040	1,489	1,069	1,275	
80+	1,032	2,538	1,324	2,161	419	1,959	1,366	1,538	690	2,190	1,325	1,751	1,213	655	928	
All	230	702	479	275	178	674	555	252	204	687	517	263	292	248	269	
Age Adj	243	986	751	438	161	819	793	343	196	899	775	383	328	235	275	

1997-1999

0-4	10	16	.	*	*	13	10	*	*	14	*	*	11	*	*
5-9	*	10	*	*	*	11	*	*	*	11	*	*	*	*	*
10-14	13	21	22	*	12	29	*	18	12	25	13	13	14	14	14
15-19	21	64	20	22	21	60	26	35	21	62	23	29	27	26	26
20-29	51	220	60	78	41	187	93	63	46	204	77	70	73	61	67
30-39	101	527	199	115	68	351	172	93	83	435	185	103	155	105	130
40-49	184	1,089	671	213	125	684	548	178	156	903	627	199	311	205	256
50-59	397	2,102	1,788	571	298	1,591	1,512	443	355	1,876	1,695	524	646	491	566
60-64	705	2,961	2,403	1,044	556	2,764	2,886	907	628	2,861	2,648	975	1,020	871	944
65-69	999	3,066	2,261	1,601	725	3,187	3,224	1,236	859	3,128	2,753	1,415	1,297	1,081	1,187
70-79	1,417	3,558	2,534	2,416	851	3,610	2,853	1,760	1,136	3,587	2,643	2,115	1,754	1,256	1,500
80+	1,444	3,038	1,262	2,542	598	2,543	1,181	1,773	983	2,751	1,220	2,095	1,632	892	1,254
All	275	745	454	286	210	730	515	258	242	737	485	271	335	283	308
Age Adj	288	1,037	692	446	186	874	719	341	229	952	709	386	371	261	308

*Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

Table A.6
Incident Counts of Reported ESRD Patients: by Primary Diagnosis
 1996-1999, grouped by age, gender, & race

DIABETES	Males					Females					Both Genders				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-4	*	*	.	.	10	*	*	.	*	18	17	10	.	*	28
5-9	*	*	.	.	*	*	*	.	.	*
10-14	.	*	.	.	*	.	*	.	.	*	.	*	.	.	*
15-19	11	*	.	.	14	10	12	.	.	22	21	15	.	.	36
20-29	568	269	*	*	847	605	363	17	17	1,002	1,173	632	20	24	1,849
30-39	3,041	902	79	70	4,092	1,942	883	66	64	2,955	4,983	1,785	145	134	7,047
40-49	5,688	2,581	276	237	8,782	3,914	2,583	260	202	6,959	9,602	5,164	536	439	15,741
50-59	9,465	4,752	484	582	15,283	7,934	5,784	528	487	14,733	17,399	10,536	1,012	1,069	30,016
60-64	5,962	2,628	201	349	9,140	6,079	4,041	305	391	10,816	12,041	6,669	506	740	19,956
65-69	6,905	2,426	153	402	9,886	7,185	4,137	279	473	12,074	14,090	6,563	432	875	21,960
70-79	11,477	2,944	187	627	15,235	11,850	5,580	329	802	18,561	23,327	8,524	516	1,429	33,796
80+	2,803	663	28	185	3,679	2,957	1,444	80	233	4,714	5,760	2,107	108	418	8,393
All	45,928	17,171	1,411	2,459	66,969	42,486	24,839	1,864	2,670	71,859	88,414	42,010	3,275	5,129	138,828
HYPERTENSION															
0-4	*	*	.	.	*	*	*	.	.	14	*	10	*	.	20
5-9	.	*	.	.	*	*	*	.	.	*	*	*	.	.	*
10-14	*	*	.	.	*	*	*	.	*	10	*	*	.	*	17
15-19	21	71	*	*	95	22	43	.	*	66	43	114	*	*	161
20-29	311	773	*	45	1,138	133	413	11	19	576	444	1,186	20	64	1,714
30-39	650	2,071	27	76	2,824	335	1,174	11	50	1,570	985	3,245	38	126	4,394
40-49	1,317	3,636	48	124	5,125	687	2,077	31	111	2,906	2,004	5,713	79	235	8,031
50-59	2,321	3,330	52	189	5,892	1,461	2,372	26	142	4,001	3,782	5,702	78	331	9,893
60-64	2,145	1,616	28	130	3,919	1,408	1,579	26	97	3,110	3,553	3,195	54	227	7,029
65-69	3,874	1,584	36	150	5,644	2,457	1,852	34	156	4,499	6,331	3,436	70	306	10,143
70-79	11,814	2,916	65	456	15,251	7,902	3,826	77	369	12,174	19,716	6,742	142	825	27,425
80+	6,726	1,194	25	267	8,212	5,439	2,107	26	227	7,799	12,165	3,301	51	494	16,011
All	29,186	17,199	291	1,439	48,115	19,855	15,455	244	1,173	36,727	49,041	32,654	535	2,612	84,842
GLOMERULONEPHRITIS															
0-4	24	*	.	*	35	19	*	.	*	26	43	11	.	*	61
5-9	40	16	*	*	60	50	17	*	*	73	90	33	*	*	133
10-14	86	29	*	*	125	78	64	*	*	149	164	93	*	10	274
15-19	249	175	*	25	452	177	121	*	20	322	426	296	*	45	774
20-29	992	612	27	113	1,744	594	452	26	87	1,159	1,586	1,064	53	200	2,903
30-39	1,448	933	34	161	2,576	765	656	37	144	1,602	2,213	1,589	71	305	4,178
40-49	1,914	1,171	60	160	3,305	1,000	700	26	170	1,896	2,914	1,871	86	330	5,201
50-59	1,976	757	40	148	2,921	1,161	471	22	118	1,772	3,137	1,228	62	266	4,693
60-64	1,151	266	14	47	1,478	589	218	16	51	874	1,740	484	30	98	2,352
65-69	1,335	238	15	74	1,662	802	218	14	56	1,090	2,137	456	29	130	2,752
70-79	3,051	324	21	137	3,533	1,779	371	22	102	2,274	4,830	695	43	239	5,807
80+	1,292	104	*	58	1,458	858	144	*	43	1,050	2,150	248	*	101	2,508
All	13,558	4,631	224	936	19,349	7,872	3,437	176	802	12,287	21,430	8,068	400	1,738	31,636
CYSTIC KIDNEY															
0-4	21	*	.	.	26	26	*	.	*	32	47	*	.	*	58
5-9	11	*	*	.	14	17	*	.	.	20	28	*	*	.	34
10-14	18	*	.	.	22	22	*	.	*	24	40	*	.	*	46
15-19	17	*	.	.	23	19	*	.	*	23	36	*	.	*	46
20-29	35	12	.	*	49	48	*	.	*	55	83	17	.	*	104
30-39	299	50	*	13	364	189	47	.	*	240	488	97	*	17	604
40-49	973	147	*	26	1,152	704	159	*	20	888	1,677	306	11	46	2,040
50-59	976	131	*	24	1,138	864	140	*	22	1,028	1,840	271	*	46	2,166
60-64	300	49	*	*	361	307	47	*	*	364	607	96	*	18	725
65-69	291	40	.	11	342	278	38	*	*	325	569	78	*	19	667
70-79	420	65	*	12	500	422	70	*	10	503	842	135	*	22	1,003
80+	146	32	*	*	182	125	24	*	*	152	271	56	*	*	334
All	3,507	543	24	99	4,173	3,021	541	11	81	3,654	6,528	1,084	35	180	7,827

*Values for cells with fewer than 10 patients are suppressed.
 ." Zero patients in this cell.

Table A.6 (continued)

Incident Counts of Reported ESRD Patients: by Primary Diagnosis

1996-1999, grouped by age, gender, & race

OTHER UROLOGIC	Males					Females					Both Genders				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-4	*	*	.	.	*	*	*	.	.	*	10	*	.	.	12
5-9	11	*	.	.	16	11	*	.	.	14	22	*	.	.	30
10-14	30	*	.	.	35	28	*	.	*	36	58	10	.	*	71
15-19	42	*	.	*	50	48	*	.	.	55	90	14	.	*	105
20-29	120	22	*	*	150	165	17	*	*	187	285	39	*	*	337
30-39	182	43	*	*	237	207	19	*	*	232	389	62	*	10	469
40-49	223	49	*	*	279	236	51	*	*	296	459	100	*	13	575
50-59	315	75	*	*	402	271	66	*	17	359	586	141	*	25	761
60-64	255	47	*	*	316	152	24	*	*	185	407	71	*	15	501
65-69	331	91	*	12	436	189	41	*	11	242	520	132	*	23	678
70-79	968	141	*	20	1,136	385	52	*	19	459	1,353	193	10	39	1,595
80+	583	72	*	11	669	159	38	.	*	203	742	110	*	17	872
All	3,067	558	32	77	3,734	1,854	324	17	77	2,272	4,921	882	49	154	6,006
OTHER CAUSE															
0-4	209	60	*	*	278	115	38	*	*	160	324	98	*	12	438
5-9	114	35	.	*	153	75	25	*	*	104	189	60	*	*	257
10-14	198	71	*	*	279	129	53	*	12	196	327	124	*	18	475
15-19	257	100	*	*	371	207	120	*	22	355	464	220	13	29	726
20-29	614	421	*	29	1,069	573	633	21	57	1,284	1,187	1,054	26	86	2,353
30-39	853	1,233	27	30	2,143	799	1,122	21	54	1,996	1,652	2,355	48	84	4,139
40-49	1,292	1,437	31	42	2,802	1,233	1,027	23	61	2,344	2,525	2,464	54	103	5,146
50-59	1,804	755	26	41	2,626	1,603	623	35	48	2,309	3,407	1,378	61	89	4,935
60-64	1,200	281	14	26	1,521	1,008	301	*	18	1,336	2,208	582	23	44	2,857
65-69	1,651	257	*	41	1,957	1,254	262	13	34	1,563	2,905	519	21	75	3,520
70-79	3,810	469	15	78	4,372	2,744	448	22	64	3,278	6,554	917	37	142	7,650
80+	1,579	177	*	34	1,796	1,211	195	*	21	1,432	2,790	372	11	55	3,228
All	13,581	5,296	144	346	19,367	10,951	4,847	161	398	16,357	24,532	10,143	305	744	35,724
UNKNOWN CAUSE															
0-4	*	*	.	*	10	*	*	.	.	*	13	*	.	*	18
5-9	10	*	.	.	12	*	*	.	.	15	19	*	.	.	27
10-14	13	15	.	*	29	37	16	.	*	56	50	31	.	*	85
15-19	52	27	.	.	79	51	27	.	*	85	103	54	.	*	164
20-29	221	128	*	19	371	125	71	*	11	210	346	199	*	30	581
30-39	258	266	*	19	550	180	158	*	20	364	438	424	13	39	914
40-49	365	339	12	28	744	279	226	*	31	545	644	565	21	59	1,289
50-59	530	258	11	24	823	366	193	*	35	601	896	451	18	59	1,424
60-64	375	130	*	17	526	281	106	*	24	419	656	236	12	41	945
65-69	554	113	*	23	698	365	122	10	14	511	919	235	18	37	1,209
70-79	1,722	264	11	52	2,049	1,107	262	14	48	1,431	2,829	526	25	100	3,480
80+	1,126	137	*	35	1,301	891	196	*	27	1,120	2,017	333	*	62	2,421
All	5,234	1,680	59	219	7,192	3,696	1,386	63	220	5,365	8,930	3,066	122	439	12,557
MISSING CAUSE															
0-4	30	10	.	.	40	34	*	.	*	39	64	14	.	*	79
5-9	37	*	.	*	49	22	*	.	*	30	59	15	.	*	79
10-14	65	17	.	.	82	35	15	.	*	52	100	32	.	*	134
15-19	64	27	.	*	92	58	20	*	*	81	122	47	*	*	173
20-29	124	71	*	*	204	127	64	.	11	202	251	135	*	18	406
30-39	286	153	*	16	456	211	99	*	20	332	497	252	*	36	788
40-49	404	232	*	22	662	289	134	*	20	448	693	366	*	42	1,110
50-59	401	210	*	21	637	317	161	*	14	498	718	371	11	35	1,135
60-64	191	95	*	*	294	187	135	*	11	339	378	230	*	18	633
65-69	124	50	*	*	180	127	72	*	*	203	251	122	*	*	383
70-79	211	78	*	*	297	221	122	*	*	352	432	200	*	13	649
80+	104	27	.	*	134	94	53	*	*	151	198	80	*	*	285
All	2,041	978	15	93	3,127	1,722	886	26	93	2,727	3,763	1,864	41	186	5,854

*Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

Table A.7
Incident Rates of Reported ESRD: by Primary Diagnosis
 1996-1999, per ten million population, adjusted for & grouped by age, gender, & race

	Specific Rates (Unadjusted)								Rates Adjusted for:							
	Males				Females				Gender				Race		Gender & Race	
	White	Black	N Am	Asian	White	Black	N Am	Asian	White	Black	N Am	Asian	Male	Female	Race	
0-4	*	*	.	.	*	14	.	.	*	*	*	.	.	*	*	
5-9	*	*	
10-14	.	*	.	.	.	*	
15-19	*	*	.	.	*	20	.	.	*	13	.	.	*	*	*	
20-29	96	263	39	22	106	336	229	50	99	301	137	35	114	132	123	
30-39	429	855	1,073	202	277	741	904	166	349	793	986	184	477	336	405	
40-49	845	2,944	4,659	805	578	2,535	4,163	606	719	2,852	4,574	728	1,175	881	1,024	
50-59	2,058	9,649	13,739	3,337	1,649	9,368	13,696	2,478	1,892	9,764	14,201	3,020	3,254	2,848	3,046	
60-64	3,542	15,052	17,408	6,077	3,301	17,298	23,153	5,708	3,416	16,198	20,294	5,880	5,222	5,350	5,291	
65-69	4,432	15,175	17,281	9,140	3,956	19,317	26,083	7,876	4,196	17,292	21,796	8,499	6,100	6,265	6,192	
70-79	4,697	14,505	15,528	10,786	3,650	18,352	21,255	10,063	4,131	16,244	17,924	10,535	6,226	5,867	6,051	
80+	2,662	8,309	5,332	7,901	1,408	8,479	8,558	7,312	1,907	8,216	6,972	7,321	3,377	2,572	2,968	
All	1,053	2,644	3,040	1,240	939	3,455	3,938	1,249	995	3,071	3,493	1,245	1,274	1,306	1,290	
Age Adj	1,074	3,858	4,667	1,960	845	4,234	5,606	1,713	948	4,072	5,200	1,824	1,387	1,216	1,294	
HYPERTENSION																
0-4	*	*	.	.	*	12	50	.	.	*	.	.	.	*	*	
5-9	.	*	.	.	*	*	
10-14	*	*	.	.	*	*	.	*	*	*	*	
15-19	*	117	22	13	*	73	.	*	*	94	.	.	21	16	18	
20-29	53	757	116	142	23	382	148	56	37	567	134	96	147	71	107	
30-39	92	1,964	367	219	48	985	151	130	69	1,457	257	173	336	171	250	
40-49	196	4,148	810	421	101	2,038	496	333	149	3,129	664	384	727	366	539	
50-59	505	6,762	1,476	1,084	304	3,842	674	722	414	5,320	1,099	941	1,354	790	1,061	
60-64	1,274	9,255	2,425	2,263	765	6,759	1,974	1,416	1,013	7,980	2,203	1,832	2,340	1,564	1,939	
65-69	2,487	9,908	4,066	3,410	1,353	8,647	3,179	2,597	1,908	9,263	3,614	2,997	3,483	2,347	2,902	
70-79	4,835	14,367	5,398	7,844	2,434	12,583	4,975	4,630	3,669	13,649	5,232	6,434	6,305	3,874	5,062	
80+	6,388	14,963	4,761	11,404	2,591	12,372	2,781	7,124	4,331	13,510	3,770	8,903	7,438	3,987	5,675	
All	669	2,649	627	726	439	2,150	515	549	552	2,387	571	634	915	667	789	
Age Adj	731	3,803	1,070	1,273	364	2,640	779	810	515	3,187	910	1,004	1,059	595	791	
GLOMERULONEPHRITIS																
0-4	*	10	.	28	*	*	.	12	*	*	.	.	*	*	*	
5-9	13	25	22	18	16	27	45	25	15	26	.	.	14	18	16	
10-14	28	48	102	31	26	109	42	32	27	79	.	31	31	37	34	
15-19	79	288	66	160	60	206	90	131	69	246	.	144	109	81	95	
20-29	168	599	348	356	104	418	350	254	135	508	349	300	232	151	191	
30-39	204	885	462	464	109	550	507	374	155	713	484	418	303	179	239	
40-49	284	1,336	1,013	543	148	687	416	510	216	1,015	728	531	439	235	334	
50-59	430	1,537	1,135	849	241	763	571	600	338	1,137	856	735	598	328	459	
60-64	684	1,523	1,213	818	320	933	1,215	744	498	1,221	1,224	772	800	423	607	
65-69	857	1,489	1,694	1,683	442	1,018	1,309	932	644	1,248	1,493	1,312	977	542	754	
70-79	1,249	1,596	1,744	2,357	548	1,220	1,421	1,280	897	1,409	1,636	1,842	1,355	671	1,006	
80+	1,227	1,303	762	2,477	409	846	535	1,349	784	1,053	0	1,902	1,239	499	861	
All	311	713	483	472	174	478	372	375	241	590	427	422	368	223	294	
Age Adj	321	858	645	624	160	524	460	430	232	684	547	514	396	213	295	

*Values for cells with fewer than 10 patients are suppressed.
 ." Zero patients in this cell.

Table A.7 (continued)

Incident Rates of Reported ESRD: by Primary Diagnosis

1996-1999, per ten million population, adjusted for & grouped by age, gender, & race

	Specific Rates (Unadjusted)								Rates Adjusted for:							
	Males				Females				Gender				Race		Gender & Race	
	White	Black	N Am	Asian	White	Black	N Am	Asian	White	Black	N Am	Asian	Male	Female	Gender & Race	
CYSTIC KIDNEY																
0-4	*	*	.	.	*	*	.	.	*	*	
5-9	*	*	22	.	*	*	.	.	*	.	.	.	*	*	*	
10-14	*	*	.	.	*	*	.	*	*	.	.	.	*	*	*	
15-19	*	*	.	.	*	*	.	*	*	.	.	.	*	*	*	
20-29	*	12	.	*	*	*	.	*	*	*	.	.	*	*	*	
30-39	42	47	27	37	27	39	.	10	34	43	.	24	42	27	34	
40-49	145	168	101	88	104	156	80	60	126	167	91	77	147	111	129	
50-59	212	266	199	138	180	227	52	112	195	246	.	124	216	182	198	
60-64	178	281	260	157	167	201	76	131	172	239	.	144	191	168	179	
65-69	187	250	.	250	153	177	93	133	170	213	.	193	196	155	175	
70-79	172	320	249	206	130	230	65	125	150	275	.	151	192	141	166	
80+	139	401	381	85	60	141	107	63	93	259	.	.	161	70	115	
All	80	84	52	50	67	75	23	38	73	79	37	44	79	66	73	
Age Adj	81	116	80	64	63	88	32	45	71	100	53	54	83	65	73	
OTHER UROLOGIC																
0-4	*	*	.	.	*	*	.	.	*	*	
5-9	*	*	.	.	*	*	.	.	*	.	.	.	*	*	*	
10-14	*	*	.	.	*	*	.	19	*	*	.	.	*	*	*	
15-19	13	12	.	*	16	12	.	.	15	12	.	.	13	15	14	
20-29	20	22	26	19	29	16	40	*	25	19	.	.	20	26	23	
30-39	26	41	95	14	29	16	14	13	28	28	.	14	28	27	27	
40-49	33	56	34	17	35	50	16	24	34	53	.	20	36	37	36	
50-59	68	152	114	46	56	107	130	86	64	135	.	66	82	66	73	
60-64	151	269	433	157	83	103	228	88	116	184	.	122	169	87	127	
65-69	212	569	226	273	104	191	93	183	157	376	.	226	260	118	187	
70-79	396	695	581	344	119	171	194	238	260	429	375	281	443	130	283	
80+	554	902	571	470	76	223	.	188	307	546	.	329	590	98	338	
All	70	86	69	39	41	45	36	36	55	64	37	52	71	41	56	
Age Adj	76	137	114	63	38	54	47	46	53	88	53	76	81	39	56	
OTHER CAUSE																
0-4	67	103	25	45	39	67	75	23	53	85	.	34	71	42	56	
5-9	36	55	.	24	25	40	23	19	30	48	.	0	37	26	32	
10-14	63	117	81	37	44	90	42	77	53	104	.	57	69	51	60	
15-19	81	165	155	45	70	204	135	144	76	185	144	97	91	90	91	
20-29	104	412	64	91	100	586	283	167	102	502	177	132	143	166	155	
30-39	120	1,169	367	86	114	941	288	140	117	1,050	327	114	254	221	237	
40-49	192	1,639	523	143	182	1,008	368	183	188	1,320	448	166	380	290	333	
50-59	392	1,533	738	235	333	1,009	908	244	369	1,267	838	250	543	426	482	
60-64	713	1,609	1,213	453	547	1,288	683	263	628	1,447	934	359	822	632	724	
65-69	1,060	1,608	904	932	691	1,223	1,215	566	872	1,411	1,067	742	1,124	759	937	
70-79	1,559	2,311	1,246	1,342	845	1,473	1,421	803	1,205	1,888	1,331	1,105	1,664	931	1,289	
80+	1,500	2,218	1,143	1,452	577	1,145	535	659	995	1,659	824	1,024	1,533	647	1,079	
All	311	816	310	174	242	674	340	186	276	741	325	181	368	297	332	
Age Adj	325	1,008	432	261	220	731	428	217	264	858	429	232	402	282	333	

*Values for cells with fewer than 10 patients are suppressed.

." Zero patients in this cell.

Table A.7 (continued)
Incident Rates of Reported ESRD: by Primary Diagnosis
 1996-1999, per ten million population, adjusted for & grouped by age, gender, & race

UNKNOWN CAUSE																
	Specific Rates (Unadjusted)								Rates Adjusted for:							
	Males				Females				Gender				Race		Gender & Race	
	White	Black	N Am	Asian	White	Black	N Am	Asian	White	Black	N Am	Asian	Male	Female	Race	
0-4	*	*	.	*	*	*	.	.	*	.	.	.	*	.	.	*
5-9	*	*	.	.	*	*	.	.	*	.	.	.	*	*	.	*
10-14	*	25	.	*	12	27	.	19	*	26	.	.	*	15	11	
15-19	16	44	.	.	17	46	.	46	17	45	.	.	19	22	21	
20-29	37	125	39	60	22	66	40	32	29	95	.	46	50	28	38	
30-39	36	252	95	55	26	133	82	52	31	191	89	54	65	41	52	
40-49	54	387	203	95	41	222	144	93	48	307	178	96	101	68	84	
50-59	115	524	312	138	76	313	182	178	97	424	256	160	174	113	142	
60-64	223	745	346	296	153	454	607	350	187	596	477	328	293	203	247	
65-69	356	707	904	523	201	570	935	233	277	637	929	375	412	256	332	
70-79	705	1,301	913	894	341	862	904	602	528	1,092	922	756	807	427	612	
80+	1,069	1,717	571	1,495	424	1,151	642	847	729	1,430	.	1,180	1,151	533	835	
All	120	259	127	110	82	193	133	103	100	224	130	107	137	97	117	
Age Adj	130	362	202	179	71	228	192	135	95	289	197	152	157	89	117	
MISSING CAUSE																
0-4	*	17	.	.	12	*	.	*	11	12	.	.	10	11	10	
5-9	12	13	.	24	*	11	.	*	*	12	.	.	12	*	*	
10-14	21	28	.	.	12	26	.	13	16	27	.	.	21	13	17	
15-19	20	44	.	*	20	34	22	13	20	39	.	.	23	21	22	
20-29	21	70	26	22	22	59	.	32	22	65	.	26	27	27	27	
30-39	40	145	14	46	30	83	27	52	35	113	.	49	53	38	45	
40-49	60	265	68	75	43	132	80	60	51	200	.	68	88	55	71	
50-59	87	426	142	120	66	261	156	71	76	349	152	99	133	92	112	
60-64	113	544	87	122	102	578	455	161	107	561	.	143	168	168	168	
65-69	80	313	113	114	70	336	187	33	75	325	.	.	111	103	107	
70-79	86	384	83	120	68	401	194	75	77	397	.	97	127	112	120	
80+	99	338	.	128	45	311	107	94	71	323	.	.	128	81	104	
All	47	151	32	47	38	123	55	44	42	136	44	45	59	50	54	
Age Adj	47	191	43	56	36	142	75	47	41	166	61	51	63	48	55	

*Values for cells with fewer than 10 patients are suppressed.
 "." Zero patients in this cell.

Table A.8

Mean Age at Start of ESRD Therapy*by demographic characteristics & primary diagnosis*

	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-19	12.5	12.0	12.4	12.3	12.4	12.2	12.3	12.2	12.1	12.3
20-44	34.6	34.8	34.9	34.8	35.0	35.2	35.4	35.4	35.5	35.6
45-64	56.0	56.0	55.9	55.7	55.6	55.6	55.6	55.6	55.5	55.5
65-74	69.2	69.4	69.4	69.4	69.5	69.5	69.6	69.6	69.6	69.6
75+	79.6	79.5	79.7	79.7	79.7	79.8	79.9	80.0	80.1	80.3
Male	57.2	57.9	58.4	58.4	58.2	58.5	59.2	60.2	60.3	60.7
Female	59.1	59.9	60.1	60.0	60.0	60.4	60.8	61.7	61.8	61.9
White	59.4	60.3	60.8	61.0	61.4	61.7	62.1	63.1	63.1	63.4
Black	55.8	56.4	56.5	56.8	56.0	55.5	56.5	57.0	57.2	57.2
Native American	55.7	56.4	57.9	57.8	56.2	56.2	56.4	57.4	57.8	57.6
Asian	55.8	56.7	56.5	57.2	58.1	59.7	60.5	60.4	60.8	61.5
Other/unknown	44.1	47.3	48.8	50.1	49.6	52.8	52.3	53.0	51.6	52.3
Hispanic						56.2	57.0	57.4	57.9	58.3
Non-Hispanic						59.7	60.3	61.3	61.3	61.6
Diabetes	58.3	59.1	59.3	59.6	60.0	60.4	60.9	61.6	61.8	62.1
Hypertension	64.5	65.0	64.8	65.0	64.9	65.0	65.2	66.1	66.1	66.4
Glomerulonephritis	51.6	52.6	52.0	51.7	52.9	52.5	53.0	53.3	53.1	53.8
Cystic kidney	54.1	53.6	54.5	53.8	55.1	53.6	54.1	54.5	54.1	54.8
Other urologic	61.8	61.1	60.5	59.6	59.4	59.4	59.7	60.0	61.2	60.6
Other cause	52.1	52.6	53.4	52.5	52.9	53.3	53.9	55.1	55.3	55.6
Unknown cause	60.6	60.7	61.2	60.1	59.3	61.5	61.2	62.7	62.3	63.7
Missing cause	48.6	48.1	50.3	57.9	51.8	52.7	50.2	53.8	48.4	46.9
All	58.0	59.0	59.2	59.3	59.1	59.4	60.0	61.0	61.0	61.3

Table A.9

Incidence of Reported ESRD: All Patients, by Detailed Primary Diagnosis

1995-1999, row percent

	Total Patients	Percent Incident	Median Age	Percent Males	Percent White	Black	Asian	N Am	Tx 1st yr	Died 1st yr
All ESRD, (reference)	406,310	100.0	63	53.2	62.5	30.2	3.4	1.5	5.3	22.8
Diabetes	172,991	43.7	63	48.2	62.2	29.4	3.6	2.3	3.1	22.4
Type 1, juvenile type	28,390	7.2	50	51.9	70.7	23.8	2.1	1.4	10.9	17.3
Type 2, adult-onset or unspecified type	144,601	36.5	65	47.5	60.5	30.5	3.9	2.5	1.5	23.4
Glomerulonephritis	40,478	10.2	54	60.9	65.7	25.0	5.3	1.2	11.6	12.9
Focal glomerulosclerosis, focal GN	9,471	2.4	48	61.1	57.4	37.1	2.6	1.0	13.3	9.7
Membranous nephropathy	1,998	0.5	58	66.7	68.9	25.9	2.5	0.9	11.2	12.4
Membranoproliferative GN, types 1&2	1,681	0.4	48	58.7	72.8	18.4	4.3	1.8	17.3	10.6
IgA nephropathy, Berger's disease	2,984	0.8	41	67.3	75.1	7.8	11.7	1.8	28.5	4.5
IgM nephropathy	309	0.1	42	68.0	74.1	9.7	12.3	1.3	28.2	3.6
Rapidly progressive GN	1,698	0.4	62	51.2	79.7	12.9	3.0	1.8	6.5	19.1
Goodpasture's Syndrome	510	0.1	57	45.3	88.6	7.1	1.8	1.2	5.7	21.4
Post infectious GN, SBE	355	0.1	54	67.6	76.9	15.8	3.1	2.5	9.6	15.2
Glomerulonephritis (GN)	20,216	5.1	59	60.8	64.8	24.5	6.4	1.2	8.2	15.2
Other proliferative GN	1,256	0.3	53	55.2	72.1	19.7	4.2	1.2	12.8	12.9
Secondary GN/vasculitis	9,634	2.4	46	32.6	60.4	32.8	3.2	1.3	7.0	18.8
Lupus erythematosus (SLE nephritis)	4,806	1.2	38	18.0	43.0	47.7	4.7	1.1	8.7	12.3
Polyarteritis	231	0.1	64	51.9	80.1	12.1	4.8	2.2	2.2	25.1
Wegener's granulomatosis	1,086	0.3	64	59.8	89.6	7.2	1.3	1.0	5.5	22.1
Henoch-Schonlein syndrome	164	.	30	56.1	84.1	6.7	4.3	2.4	23.8	7.3
Vasculitis and its derivatives	1,029	0.3	68	48.1	85.3	9.6	1.7	2.6	2.1	29.6
Scleroderma	823	0.2	56	22.5	76.9	20.2	1.2	1.1	3.0	36.2
Hemolytic uremic syndrome	758	0.2	47	35.1	78.2	18.1	1.1	0.9	9.6	19.9
Nephropathy from heroin /related abuse	311	0.1	44	69.1	30.5	65.0	1.3	1.3	1.9	18.0
Secondary GN, other	426	0.1	53	58.2	59.6	34.0	2.6	1.9	6.1	24.2
Interstitial nephritis/pyelonephritis	16,197	4.1	65	56.0	78.8	15.9	2.7	0.7	7.2	22.3
Chronic pyelonephritis, reflux neph.	2,379	0.6	45	39.6	84.7	9.9	2.6	0.8	20.9	10.9
Analgesic abuse	917	0.2	67	37.9	77.1	18.1	2.5	0.8	4.9	18.9
Nephropathy caused by other agents	2,089	0.5	62	58.3	77.7	18.0	1.8	0.5	6.1	29.3
Nephrolithiasis, obstruction, gouty	5,279	1.3	69	72.9	77.2	16.9	3.1	0.7	2.2	26.1
Nephrocalcinosis	294	0.1	67	50.3	79.6	13.6	3.1	0.3	7.5	20.4
Chronic interstitial nephritis	4,532	1.1	65	48.9	77.7	16.9	3.0	0.8	7.5	20.3
Acute interstitial nephritis	707	0.2	68	50.1	82.5	14.4	1.1	0.6	2.4	30.7
Hypertensive/large vessel disease	104,861	26.5	70	56.7	56.8	38.0	3.0	0.7	1.8	25.6
Hypertension (no primary renal disease)	92,637	23.4	69	56.5	52.2	42.3	3.2	0.7	2.0	24.1
Renal artery stenosis or occlusion	8,202	2.1	73	54.2	91.2	6.5	1.4	0.4	0.6	37.3
Cholesterol emboli, renal emboli	4,022	1.0	73	66.6	94.1	3.8	1.1	0.5	0.4	36.6
Cystic/hereditary/congenital diseases	13,547	3.4	50	56.9	80.3	14.3	2.3	0.6	23.4	6.4
Polycystic kidneys, adult (dominant)	9,481	2.4	54	53.4	81.9	13.6	2.3	0.4	18.7	6.6
Polycystic, infantile (recessive)	214	0.1	19	46.3	79.9	15.9	1.4	.	34.1	9.3
Medullary cystic, including nephronophthisis	220	0.1	23	50.0	81.4	10.9	1.8	1.4	40.9	2.3
Alport's, other hereditary/familial disease	997	0.3	35	66.9	83.9	10.8	2.1	1.2	32.3	2.3
Tuberous sclerosis	132	.	58	50.0	69.7	23.5	2.3	1.5	8.3	20.5
Cystinosis	54	.	15	42.6	85.2	9.3	.	1.9	48.1	5.6
Primary oxalosis	52	.	42	44.2	84.6	1.9	3.8	.	32.7	7.7
Fabry's disease	74	.	43	91.9	82.4	8.1	.	5.4	25.7	8.1
Congenital nephrotic syndrome	249	0.1	24	52.2	64.7	22.1	6.4	0.8	28.9	11.6
Drash syndrome, mesangial sclerosis	33	.	35	63.6	72.7	18.2	.	3.0	15.2	6.1
Congenital obstructive uropathy	1,137	0.3	23	75.5	74.7	18.0	2.6	0.7	35.7	7.5
Renal hypoplasia, dysplasia	791	0.2	13	59.2	71.7	19.7	1.9	1.3	38.9	4.8
Prune belly syndrome	113	.	11	99.1	74.3	21.2	0.9	.	40.7	3.5
Neoplasms/tumors	7,465	1.9	69	61.3	76.7	19.9	1.5	0.7	0.9	48.5
Renal or urological neoplasms	2,157	0.5	69	73.2	78.7	18.3	1.2	0.7	1.3	40.1
Multiple myeloma	3,728	0.9	69	56.6	73.8	22.5	1.8	0.7	0.1	56.7
Light chain nephropathy	468	0.1	70	61.5	77.6	18.6	2.4	0.6	1.1	41.7
Amyloidosis	1,112	0.3	67	54.0	82.0	15.2	0.9	0.7	2.9	40.4
Miscellaneous conditions	15,192	3.8	56	63.6	57.7	38.4	1.3	0.7	3.1	36.7
Complication post bone marrow/other txp	398	0.1	54	66.6	87.9	8.8	2.0	0.3	17.1	22.9
Sickle cell disease/anemia or trait	469	0.1	39	52.0	2.8	95.7	0.6	0.6	2.1	20.9
AIDS nephropathy	4,271	1.1	39	71.7	7.4	89.2	0.2	0.6	.	38.7
Traumatic/surgical loss of kidney(s)	443	0.1	66	67.7	81.3	14.9	1.4	0.7	3.2	23.5
Hepatorenal syndrome	623	0.2	55	68.1	77.4	14.6	1.9	2.6	11.1	53.1
Tubular necrosis (no recovery)	4,987	1.3	69	58.9	82.3	14.3	1.4	0.6	0.8	39.8
Post-partum failure, other renal disorders	4,001	1.0	66	60.8	78.5	16.6	2.3	0.7	6.9	32.7
Etiology uncertain	15,603	3.9	68	57.6	69.1	23.8	3.6	1.0	4.6	27.4
Missing	10,342	.	52	53.3	53.9	32.6	2.6	0.6	33.8	19.3

On our website: detailed primary diagnosis tables for patients <20, 20-64, and 65+ (Tables A.f-A.k).

Table A.10

Incidence of Reported ESRD: All Patients, by Detailed Primary Diagnosis

1995-1999, column percent

	Total Patients	Counts				N Am	Percent			
		White	Black	Asian	N Am		White	Black	Asian	N Am
All ESRD, (reference)	406,310	254,056	122,846	13,728	5,943	100.0	100.0	100.0	100.0	
Diabetes	172,991	107,583	50,792	6,226	4,028	43.3	42.5	46.3	68.5	
Type 1, juvenile type	28,390	20,070	6,746	599	409	8.1	5.6	4.5	7.0	
Type 2, adult-onset or unspecified type	144,601	87,513	44,046	5,627	3,619	35.2	36.9	41.8	61.5	
Glomerulonephritis	40,478	26,583	10,119	2,165	502	10.7	8.5	16.1	8.5	
Focal glomerulosclerosis, focal GN	9,471	5,435	3,512	243	90	2.2	2.9	1.8	1.5	
Membranous nephropathy	1,998	1,376	518	50	18	0.6	0.4	0.4	0.3	
Membranoproliferative GN, types 1&2	1,681	1,224	309	72	31	0.5	0.3	0.5	0.5	
IgA nephropathy, Berger's disease	2,984	2,242	232	349	54	0.9	0.2	2.6	0.9	
IgM nephropathy	309	229	30	38	*	0.1	.	0.3	0.1	
Rapidly progressive GN	1,698	1,354	219	51	31	0.5	0.2	0.4	0.5	
Goodpasture's Syndrome	510	452	36	*	*	0.2	.	0.1	0.1	
Post infectious GN, SBE	355	273	56	11	*	0.1	.	0.1	0.2	
Glomerulonephritis (GN)	20,216	13,092	4,959	1,289	244	5.3	4.2	9.6	4.1	
Other proliferative GN	1,256	906	248	53	15	0.4	0.2	0.4	0.3	
Secondary GN/vasculitis	9,634	5,815	3,160	306	128	2.3	2.6	2.3	2.2	
Lupus erythematosus (SLE nephritis)	4,806	2,066	2,294	224	53	0.8	1.9	1.7	0.9	
Polyarteritis	231	185	28	11	*	0.1	.	0.1	0.1	
Wegener's granulomatosis	1,086	973	78	14	11	0.4	0.1	0.1	0.2	
Henoch-Schonlein syndrome	164	138	11	*	*	0.1	.	0.1	0.1	
Vasculitis and its derivatives	1,029	878	99	17	27	0.4	0.1	0.1	0.5	
Scleroderma	823	633	166	10	*	0.3	0.1	0.1	0.2	
Hemolytic uremic syndrome	758	593	137	*	*	0.2	0.1	0.1	0.1	
Nephropathy from heroin /related abuse	311	95	202	*	*	.	0.2	.	0.1	
Secondary GN, other	426	254	145	11	*	0.1	0.1	0.1	0.1	
Interstitial nephritis/pyelonephritis	16,197	12,756	2,579	438	117	5.1	2.2	3.3	2.0	
Chronic pyelonephritis, reflux neph.	2,379	2,015	235	63	19	0.8	0.2	0.5	0.3	
Analgesic abuse	917	707	166	23	*	0.3	0.1	0.2	0.1	
Nephropathy caused by other agents	2,089	1,623	375	37	11	0.7	0.3	0.3	0.2	
Nephrolithiasis, obstruction, gouty	5,279	4,074	893	162	38	1.6	0.7	1.2	0.6	
Nephrocalcinosis	294	234	40	*	*	0.1	.	0.1	.	
Chronic interstitial nephritis	4,532	3,520	768	136	37	1.4	0.6	1.0	0.6	
Acute interstitial nephritis	707	583	102	*	*	0.2	0.1	0.1	0.1	
Hypertensive/large vessel disease	104,861	59,593	39,852	3,148	710	24.0	33.4	23.4	12.1	
Hypertension (no primary renal disease)	92,637	48,327	39,164	2,988	657	19.4	32.8	22.2	11.2	
Renal artery stenosis or occlusion	8,202	7,481	537	115	31	3.0	0.4	0.9	0.5	
Cholesterol emboli, renal emboli	4,022	3,785	151	45	22	1.5	0.1	0.3	0.4	
Cystic/hereditary/congenital diseases	13,547	10,883	1,940	313	85	4.4	1.6	2.3	1.4	
Polycystic kidneys, adult (dominant)	9,481	7,769	1,285	219	42	3.1	1.1	1.6	0.7	
Polycystic, infantile (recessive)	214	171	34	*	.	0.1	.	.	.	
Medullary cystic, including nephronophthisis	220	179	24	*	*	0.1	.	.	0.1	
Alport's, other hereditary/familial disease	997	836	108	21	12	0.3	0.1	0.2	0.2	
Tuberous sclerosis	132	92	31	*	*	
Cystinosis	54	46	*	.	*	
Primary oxalosis	52	44	*	*	
Fabry's disease	74	61	*	.	*	.	.	.	0.1	
Congenital nephrotic syndrome	249	161	55	16	*	0.1	.	0.1	.	
Drash syndrome, mesangial sclerosis	33	24	*	.	*	
Congenital obstructive uropathy	1,137	849	205	29	*	0.3	0.2	0.2	0.1	
Renal hypoplasia, dysplasia	791	567	156	15	10	0.2	0.1	0.1	0.2	
Prune belly syndrome	113	84	24	*	
Neoplasms/tumors	7,465	5,726	1,487	112	52	2.3	1.2	0.8	0.9	
Renal or urological neoplasms	2,157	1,698	394	25	15	0.7	0.3	0.2	0.3	
Multiple myeloma	3,728	2,753	837	66	26	1.1	0.7	0.5	0.4	
Light chain nephropathy	468	363	87	11	*	0.1	0.1	0.1	0.1	
Amyloidosis	1,112	912	169	10	*	0.4	0.1	0.1	0.1	
Miscellaneous conditions	15,192	8,768	5,829	198	106	3.5	4.9	1.5	1.8	
Complication post bone marrow/other txp	398	350	35	*	*	0.1	.	0.1	.	
Sickle cell disease/anemia or trait	469	13	449	*	*	.	0.4	.	0.1	
AIDS nephropathy	4,271	315	3,809	10	25	0.1	3.2	0.1	0.4	
Traumatic/surgical loss of kidney(s)	443	360	66	*	*	0.1	0.1	.	0.1	
Hepatorenal syndrome	623	482	91	12	16	0.2	0.1	0.1	0.3	
Tubular necrosis (no recovery)	4,987	4,106	714	68	31	1.7	0.6	0.5	0.5	
Post-partum failure, other renal disorders	4,001	3,142	665	91	27	1.3	0.6	0.7	0.5	
Etiology uncertain	15,603	10,774	3,717	554	154	4.3	3.1	4.1	2.6	
Missing	10,342	5,575	3,371	268	61	

Table A.11
Incidence of Reported ESRD: Hispanics, by Detailed Primary Diagnosis
 1995-1999, row percent

	Total Patients	Percent Incident	Median Age	Percent Males	Percent White	Black	Asian	N Am	Tx 1st yr	Died 1st yr
All ESRD, (reference)	45,060	100.0	60	52.6	77.0	4.3	2.1	2.3	3.3	17.3
Diabetes	26,641	59.5	62	49.6	79.9	3.6	1.8	2.0	1.3	18.1
Type 1, juvenile type	3,024	6.8	53	51.8	76.4	4.6	2.1	2.0	4.3	15.6
Type 2, adult-onset or unspecified type	23,617	52.8	63	49.3	80.4	3.5	1.7	2.0	0.9	18.4
Glomerulonephritis	4,228	9.4	43	59.4	73.0	5.3	2.3	2.0	10.7	7.6
Focal glomerulosclerosis, focal GN	755	1.7	40	59.6	72.3	7.5	2.0	3.0	15.0	5.8
Membranous nephropathy	181	0.4	53	65.2	73.5	7.7	0.6	2.2	11.0	7.7
Membranoproliferative GN, types 1&2	190	0.4	41	59.5	75.3	5.3	2.1	1.1	13.2	8.4
IgA nephropathy, Berger's disease	344	0.8	37	57.6	76.5	2.9	2.3	1.5	16.0	3.2
IgM nephropathy	30	0.1	40	56.7	70.0	3.3	6.7	3.3	23.3	.
Rapidly progressive GN	162	0.4	48	45.1	72.8	6.2	1.2	1.9	5.6	8.6
Goodpasture's Syndrome	28	0.1	37	28.6	82.1	.	3.6	.	10.7	14.3
Post infectious GN, SBE	36	0.1	44	58.3	80.6	5.6	8.3	.	5.6	13.9
Glomerulonephritis (GN)	2,384	5.3	46	60.8	72.7	4.7	2.3	1.8	8.5	8.6
Other proliferative GN	118	0.3	39	55.1	65.3	5.1	6.8	2.5	11.9	5.1
Secondary GN/vasculitis	1,065	2.4	37	26.7	75.2	3.8	1.5	3.0	7.4	11.6
Lupus erythematosus (SLE nephritis)	738	1.6	33	17.6	73.6	4.3	1.2	2.6	8.3	9.5
Polyarteritis	16	.	59	37.5	81.3	.	.	6.3	.	6.3
Wegener's granulomatosis	60	0.1	57	70.0	71.7	5.0	5.0	5.0	1.7	18.3
Henoch-Schonlein syndrome	16	.	26	68.8	75.0	.	6.3	6.3	43.8	.
Vasculitis and its derivatives	74	0.2	58	40.5	89.2	1.4	.	1.4	4.1	17.6
Scleroderma	59	0.1	50	18.6	89.8	1.7	1.7	.	8.5	22.0
Hemolytic uremic syndrome	48	0.1	40	35.4	75.0	2.1	0.0	8.3	2.1	12.5
Nephropathy from heroin /related abuse	26	0.1	38	76.9	57.7	7.7	3.8	7.7	.	7.7
Secondary GN, other	28	0.1	48	60.7	71.4	3.6	3.6	3.6	3.6	28.6
Interstitial nephritis/pyelonephritis	1,195	2.7	60	57.9	74.6	3.5	3.8	1.4	5.6	20.3
Chronic pyelonephritis, reflux neph.	184	0.4	33	38.6	77.7	4.3	3.8	1.1	15.8	7.6
Analgesic abuse	64	0.1	65	46.9	71.9	3.1	10.9	.	3.1	18.8
Nephropathy caused by other agents	136	0.3	63	56.6	69.9	1.5	3.7	2.9	3.7	30.9
Nephrolithiasis, obstruction, gouty	458	1.0	66	74.0	73.6	4.8	2.6	1.5	0.9	24.5
Nephrocalcinosis	19	.	57	52.6	57.9	.	10.5	.	5.3	15.8
Chronic interstitial nephritis	292	0.7	57	49.3	78.1	2.4	4.1	1.4	8.9	15.8
Acute interstitial nephritis	42	0.1	58	50.0	76.2	2.4	2.4	.	.	33.3
Hypertensive/large vessel disease	7,406	16.5	65	58.4	72.8	6.2	3.4	3.8	2.5	19.6
Hypertension (no primary renal disease)	7,048	15.7	64	58.7	72.6	6.4	3.2	3.8	2.6	18.9
Renal artery stenosis or occlusion	256	0.6	72	47.3	77.3	3.1	6.3	3.9	0.8	32.0
Cholesterol emboli, renal emboli	102	0.2	73	63.7	76.5	2.0	6.9	4.9	1.0	34.3
Cystic/hereditary/congenital diseases	1,239	2.8	44	56.5	76.6	4.5	1.9	1.5	14.4	4.7
Polycystic kidneys, adult (dominant)	761	1.7	51	53.6	79.2	4.5	1.6	1.7	9.3	4.5
Polycystic, infantile (recessive)	28	0.1	10	46.4	89.3	7.1	3.6	.	14.3	3.6
Medullary cystic, including nephronophthisis	18	.	16	55.6	61.1	5.6	5.6	.	27.8	.
Alport's, other hereditary/familial disease	87	0.2	24	63.2	74.7	6.9	3.4	1.1	21.8	2.3
Tuberous sclerosis	13	.	68	76.9	61.5	23.1	.	.	7.7	23.1
Cystinosis	*	.	32	50.0	25.0	.	.	25.0	25.0	.
Primary oxalosis	*	.	27	.	100.0	.	.	.	50.0	.
Fabry's disease	*	.	38	88.9	55.6	.	.	22.2	.	11.1
Congenital nephrotic syndrome	36	0.1	8	38.9	69.4	2.8	5.6	.	11.1	5.6
Drash syndrome, mesangial sclerosis	*	.	1	80.0	60.0	20.0	.	.	40.0	.
Congenital obstructive uropathy	126	0.3	19	73.0	69.0	3.2	2.4	.	25.4	5.6
Renal hypoplasia, dysplasia	137	0.3	11	51.8	75.2	2.9	1.5	0.7	24.8	5.8
Prune belly syndrome	13	.	12	100.0	84.6	.	.	.	30.8	.
Neoplasms/tumors	437	1.0	66	60.6	74.6	5.9	3.2	3.2	0.9	45.1
Renal or urological neoplasms	140	0.3	68	77.1	70.7	6.4	3.6	2.9	0.7	40.0
Multiple myeloma	211	0.5	66	52.6	76.3	5.7	2.8	2.8	.	54.0
Light chain nephropathy	23	0.1	64	52.2	65.2	4.3	8.7	8.7	.	39.1
Amyloidosis	63	0.1	63	54.0	81.0	6.3	1.6	3.2	4.8	28.6
Miscellaneous conditions	941	2.1	51	63.7	65.0	6.8	2.1	3.3	3.2	33.2
Complication post bone marrow/other txp	15	.	46	73.3	86.7	.	.	.	6.7	13.3
Sickle cell disease/anemia or trait	11	.	35	36.4	36.4	36.4	.	27.3	18.2	9.1
AIDS nephropathy	242	0.5	39	71.1	43.8	14.5	2.1	3.3	.	42.6
Traumatic/surgical loss of kidney(s)	29	0.1	48	62.1	69.0	3.4	3.4	3.4	.	10.3
Hepatorenal syndrome	74	0.2	56	78.4	70.3	2.7	2.7	2.7	9.5	47.3
Tubular necrosis (no recovery)	260	0.6	65	59.6	72.7	5.0	.	3.8	0.8	35.0
Post-partum failure, other renal disorders	310	0.7	58	58.4	73.5	2.9	3.9	2.3	5.8	24.8
Etiology uncertain	1,606	3.6	49	62.2	75.1	4.0	1.7	2.2	5.0	15.8
Missing	302	.	47	49.0	46.0	4.0	1.0	0.7	24.2	14.2

Table A.12

Incidence of Reported ESRD: Hispanics, by Detailed Primary Diagnosis

1995-1999, column percent

	Total Patients	Counts				Percent			
		White	Black	Asian	N Am	White	Black	Asian	N Am
All ESRD, (reference)	45,060	34,701	1,949	966	1,040	100.0	100.0	100.0	100.0
Diabetes	26,641	21,294	963	468	526	61.6	49.7	48.6	50.7
Type 1, juvenile type	3,024	2,311	139	65	60	6.7	7.2	6.7	5.8
Type 2, adult-onset or unspecified type	23,617	18,983	824	403	466	54.9	42.5	41.8	44.9
Glomerulonephritis	4,228	3,087	223	98	84	8.9	11.5	10.2	8.1
Focal glomerulosclerosis, focal GN	755	546	57	15	23	1.6	2.9	1.6	2.2
Membranous nephropathy	181	133	14	*	*	0.4	0.7	0.1	0.4
Membranoproliferative GN, types 1&2	190	143	10	*	*	0.4	0.5	0.4	0.2
IgA nephropathy, Berger's disease	344	263	10	*	*	0.8	0.5	0.8	0.5
IgM nephropathy	30	21	*	*	*	0.1	0.1	0.2	0.1
Rapidly progressive GN	162	118	10	*	*	0.3	0.5	0.2	0.3
Goodpasture's Syndrome	28	23	.	*	.	0.1	.	0.1	.
Post infectious GN, SBE	36	29	*	*	.	0.1	0.1	0.3	.
Glomerulonephritis (GN)	2,384	1,734	113	54	43	5.0	5.8	5.6	4.1
Other proliferative GN	118	77	*	*	*	0.2	0.3	0.8	0.3
Secondary GN/vasculitis	1,065	801	41	16	32	2.3	2.1	1.7	3.1
Lupus erythematosus (SLE nephritis)	738	543	32	*	19	1.6	1.7	0.9	1.8
Polyarteritis	16	13	.	.	*	.	.	.	0.1
Wegener's granulomatosis	60	43	*	*	*	0.1	0.2	0.3	0.3
Henoch-Schonlein syndrome	16	12	.	*	*	.	.	0.1	0.1
Vasculitis and its derivatives	74	66	*	.	*	0.2	0.1	.	0.1
Scleroderma	59	53	*	*	.	0.2	0.1	0.1	.
Hemolytic uremic syndrome	48	36	*	.	*	0.1	0.1	.	0.4
Nephropathy from heroin /related abuse	26	15	*	*	*	.	0.1	0.1	0.2
Secondary GN, other	28	20	*	*	*	0.1	0.1	0.1	0.1
Interstitial nephritis/pyelonephritis	1,195	892	42	46	17	2.6	2.2	4.8	1.6
Chronic pyelonephritis, reflux neph.	184	143	*	*	*	0.4	0.4	0.7	0.2
Analgesic abuse	64	46	*	*	.	0.1	0.1	0.7	.
Nephropathy caused by other agents	136	95	*	*	*	0.3	0.1	0.5	0.4
Nephrolithiasis, obstruction, gouty	458	337	22	12	*	1.0	1.1	1.2	0.7
Nephrocalcinosis	19	11	.	*	.	.	.	0.2	.
Chronic interstitial nephritis	292	228	*	12	*	0.7	0.4	1.2	0.4
Acute interstitial nephritis	42	32	*	*	.	0.1	0.1	0.1	.
Hypertensive/large vessel disease	7,406	5,395	458	249	280	15.6	23.6	25.9	27.0
Hypertension (no primary renal disease)	7,048	5,119	448	226	265	14.8	23.1	23.5	25.5
Renal artery stenosis or occlusion	256	198	*	16	10	0.6	0.4	1.7	1.0
Cholesterol emboli, renal emboli	102	78	*	*	*	0.2	0.1	0.7	0.5
Cystic/hereditary/congenital diseases	1,239	949	56	24	18	2.7	2.9	2.5	1.7
Polycystic kidneys, adult (dominant)	761	603	34	12	13	1.7	1.8	1.2	1.3
Polycystic, infantile (recessive)	28	25	*	*	.	0.1	0.1	0.1	.
Medullary cystic, including nephronophthisis	18	11	*	*	.	.	0.1	0.1	.
Alport's, other hereditary/familial disease	87	65	*	*	*	0.2	0.3	0.3	0.1
Tuberous sclerosis	13	*	*	.	.	.	0.2	.	.
Cystinosis	*	*	.	.	*	.	.	.	0.1
Primary oxalosis	*	*
Fabry's disease	*	*	.	.	*	.	.	.	0.2
Congenital nephrotic syndrome	36	25	*	*	.	0.1	0.1	0.2	.
Drash syndrome, mesangial sclerosis	*	*	*	.	.	.	0.1	.	.
Congenital obstructive uropathy	126	87	*	*	.	0.3	0.2	0.3	.
Renal hypoplasia, dysplasia	137	103	*	*	*	0.3	0.2	0.2	0.1
Prune belly syndrome	13	11
Neoplasms/tumors	437	326	26	14	14	0.9	1.3	1.5	1.3
Renal or urological neoplasms	140	99	*	*	*	0.3	0.5	0.5	0.4
Multiple myeloma	211	161	12	*	*	0.5	0.6	0.6	0.6
Light chain nephropathy	23	15	*	*	*	.	0.1	0.2	0.2
Amyloidosis	63	51	*	*	*	0.1	0.2	0.1	0.2
Miscellaneous conditions	941	612	64	20	31	1.8	3.3	2.1	3.0
Complication post bone marrow/other txp	15	13
Sickle cell disease/anemia or trait	11	*	*	.	*	.	0.2	.	0.3
AIDS nephropathy	242	106	35	*	*	0.3	1.8	0.5	0.8
Traumatic/surgical loss of kidney(s)	29	20	*	*	*	0.1	0.1	0.1	0.1
Hepatorenal syndrome	74	52	*	*	*	0.2	0.1	0.2	0.2
Tubular necrosis (no recovery)	260	189	13	.	10	0.5	0.7	.	1.0
Post-partum failure, other renal disorders	310	228	*	12	*	0.7	0.5	1.2	0.7
Etiology uncertain	1,606	1,206	64	28	36	3.5	3.3	2.9	3.5
Missing	302	139	12	*	*

Table A.13

Incidence of Reported ESRD: Non-Hispanics, by Detailed Primary Diagnosis

1995-1999, row percent

	Total Patients	Percent Incident	Median Age	Percent Males	Percent White	Black	Asian	N Am	Tx 1st yr	Died 1st yr
All ESRD, (reference)	361,250	100.0	64	53.3	60.7	33.5	3.5	1.4	5.6	23.5
Diabetes	146,350	41.7	63	47.9	59.0	34.0	3.9	2.4	3.4	23.2
Type 1, juvenile type	25,366	7.2	49	51.9	70.0	26.0	2.1	1.4	11.7	17.5
Type 2, adult-onset or unspecified type	120,984	34.4	65	47.1	56.6	35.7	4.3	2.6	1.6	24.4
Glomerulonephritis	36,250	10.3	55	61.1	64.8	27.3	5.7	1.2	11.8	13.5
Focal glomerulosclerosis, focal GN	8,716	2.5	48	61.3	56.1	39.6	2.6	0.8	13.2	10.0
Membranous nephropathy	1,817	0.5	59	66.8	68.4	27.7	2.7	0.8	11.2	12.9
Membranoproliferative GN, types 1&2	1,491	0.4	49	58.6	72.5	20.1	4.6	1.9	17.8	10.9
IgA nephropathy, Berger's disease	2,640	0.8	41	68.6	75.0	8.4	12.9	1.9	30.1	4.7
IgM nephropathy	279	0.1	43	69.2	74.6	10.4	12.9	1.1	28.7	3.9
Rapidly progressive GN	1,536	0.4	64	51.9	80.5	13.6	3.2	1.8	6.6	20.2
Goodpasture's Syndrome	482	0.1	59	46.3	89.0	7.5	1.7	1.2	5.4	21.8
Post infectious GN, SBE	319	0.1	54	68.7	76.5	16.9	2.5	2.8	10.0	15.4
Glomerulonephritis (GN)	17,832	5.1	60	60.8	63.7	27.2	6.9	1.1	8.2	16.1
Other proliferative GN	1,138	0.3	55	55.2	72.8	21.3	4.0	1.1	12.9	13.7
Secondary GN/vasculitis	8,569	2.4	48	33.3	58.5	36.4	3.4	1.1	7.0	19.7
Lupus erythematosus (SLE nephritis)	4,068	1.2	39	18.1	37.4	55.6	5.3	0.8	8.8	12.8
Polyarteritis	215	0.1	64	53.0	80.0	13.0	5.1	1.9	2.3	26.5
Wegener's granulomatosis	1,026	0.3	65	59.2	90.6	7.3	1.1	0.8	5.8	22.3
Henoch-Schonlein syndrome	148	0.0	32	54.7	85.1	7.4	4.1	2.0	21.6	8.1
Vasculitis and its derivatives	955	0.3	68	48.7	85.0	10.3	1.8	2.7	2.0	30.6
Scleroderma	764	0.2	57	22.8	75.9	21.6	1.2	1.2	2.6	37.3
Hemolytic uremic syndrome	710	0.2	47	35.1	78.5	19.2	1.1	0.4	10.1	20.4
Nephropathy from heroin /related abuse	285	0.1	45	68.4	28.1	70.2	1.1	0.7	2.1	18.9
Secondary GN, other	398	0.1	53	58.0	58.8	36.2	2.5	1.8	6.3	23.9
Interstitial nephritis/pyelonephritis	15,002	4.3	65	55.9	79.1	16.9	2.6	0.7	7.3	22.5
Chronic pyelonephritis, reflux neph.	2,195	0.6	47	39.6	85.3	10.3	2.6	0.8	21.4	11.2
Analgesic abuse	853	0.2	67	37.3	77.5	19.2	1.9	0.8	5.0	18.9
Nephropathy caused by other agents	1,953	0.6	62	58.4	78.2	19.1	1.6	0.4	6.3	29.2
Nephrolithiasis, obstruction, gouty	4,821	1.4	70	72.7	77.5	18.1	3.1	0.6	2.3	26.2
Nephrocalcinosis	275	0.1	68	50.2	81.1	14.5	2.5	0.4	7.6	20.7
Chronic interstitial nephritis	4,240	1.2	65	48.9	77.6	17.9	2.9	0.8	7.4	20.6
Acute interstitial nephritis	665	0.2	69	50.1	82.9	15.2	1.1	0.6	2.6	30.5
Hypertensive/large vessel disease	97,455	27.7	70	56.6	55.6	40.4	3.0	0.4	1.7	26.0
Hypertension (no primary renal disease)	85,589	24.4	69	56.3	50.5	45.2	3.2	0.5	1.9	24.5
Renal artery stenosis or occlusion	7,946	2.3	73	54.4	91.7	6.7	1.2	0.3	0.6	37.5
Cholesterol emboli, renal emboli	3,920	1.1	73	66.7	94.6	3.8	1.0	0.4	0.4	36.7
Cystic/hereditary/congenital diseases	12,308	3.5	50	56.9	80.7	15.3	2.3	0.5	24.3	6.6
Polycystic kidneys, adult (dominant)	8,720	2.5	54	53.4	82.2	14.3	2.4	0.3	19.6	6.8
Polycystic, infantile (recessive)	186	0.1	22	46.2	78.5	17.2	1.1	0.0	37.1	10.2
Medullary cystic, including nephronophthisis	202	0.1	25	49.5	83.2	11.4	1.5	1.5	42.1	2.5
Alport's, other hereditary/familial disease	910	0.3	37	67.3	84.7	11.2	2.0	1.2	33.3	2.3
Tuberous sclerosis	119	.	56	47.1	70.6	23.5	2.5	1.7	8.4	20.2
Cystinosis	50	.	15	42.0	90.0	10.0	.	.	50.0	6.0
Primary oxalosis	50	.	45	46.0	84.0	2.0	4.0	.	32.0	8.0
Fabry's disease	65	.	43	92.3	86.2	9.2	.	3.1	29.2	7.7
Congenital nephrotic syndrome	213	0.1	26	54.5	63.8	25.4	6.6	0.9	31.9	12.7
Drash syndrome, mesangial sclerosis	28	.	41	60.7	75.0	17.9	.	3.6	10.7	7.1
Congenital obstructive uropathy	1,011	0.3	24	75.8	75.4	19.9	2.6	0.8	37.0	7.7
Renal hypoplasia, dysplasia	654	0.2	13	60.7	70.9	23.2	2.0	1.4	41.9	4.6
Prune belly syndrome	100	.	11	99.0	73.0	24.0	1.0	0.0	42.0	4.0
Neoplasms/tumors	7,028	2.0	69	61.4	76.8	20.8	1.4	0.5	0.9	48.7
Renal or urological neoplasms	2,017	0.6	69	72.9	79.3	19.1	1.0	0.5	1.3	40.2
Multiple myeloma	3,517	1.0	69	56.8	73.7	23.5	1.7	0.6	0.1	56.8
Light chain nephropathy	445	0.1	70	62.0	78.2	19.3	2.0	0.2	1.1	41.8
Amyloidosis	1,049	0.3	67	54.1	82.1	15.7	0.9	0.6	2.8	41.1
Miscellaneous conditions	14,251	4.1	56	63.6	57.2	40.5	1.2	0.5	3.1	36.9
Complication post bone marrow/other txp	383	0.1	55	66.3	88.0	9.1	2.1	0.3	17.5	23.2
Sickle cell disease/anemia or trait	458	0.1	39	52.4	2.0	97.2	0.7	.	1.7	21.2
AIDS nephropathy	4,029	1.1	39	71.8	5.2	93.7	0.1	0.4	.	38.5
Traumatic/surgical loss of kidney(s)	414	0.1	67	68.1	82.1	15.7	1.2	0.5	3.4	24.4
Hepatorenal syndrome	549	0.2	55	66.7	78.3	16.2	1.8	2.6	11.3	53.9
Tubular necrosis (no recovery)	4,727	1.3	70	58.8	82.9	14.8	1.4	0.4	0.8	40.1
Post-partum failure, other renal disorders	3,691	1.1	67	61.0	78.9	17.8	2.1	0.5	7.0	33.3
Etiology uncertain	13,997	4.0	69	57.0	68.4	26.1	3.8	0.8	4.5	28.7
Missing	10,040	.	52	53.4	54.1	33.5	2.6	0.6	34.1	19.4

Table A.14

Incidence of Reported ESRD: Non-Hispanics, by Detailed Primary Diagnosis

1995-1999, column percent

	Total Counts					Percent			
	Patients	White	Black	Asian	N Am	White	Black	Asian	N Am
All ESRD, (reference)	361,250	219,355	120,897	12,762	4,903	100.0	100.0	100.0	100.0
Diabetes	146,350	86,289	49,829	5,758	3,502	40.3	42.4	46.1	72.3
Type 1, juvenile type	25,366	17,759	6,607	534	349	8.3	5.6	4.3	7.2
Type 2, adult-onset or unspecified type	120,984	68,530	43,222	5,224	3,153	32.0	36.8	41.8	65.1
Glomerulonephritis	36,250	23,496	9,896	2,067	418	11.0	8.4	16.5	8.6
Focal glomerulosclerosis, focal GN	8,716	4,889	3,455	228	67	2.3	2.9	1.8	1.4
Membranous nephropathy	1,817	1,243	504	49	14	0.6	0.4	0.4	0.3
Membranoproliferative GN, types 1&2	1,491	1,081	299	68	29	0.5	0.3	0.5	0.6
IgA nephropathy, Berger's disease	2,640	1,979	222	341	49	0.9	0.2	2.7	1.0
IgM nephropathy	279	208	29	36	*	0.1	.	0.3	0.1
Rapidly progressive GN	1,536	1,236	209	49	28	0.6	0.2	0.4	0.6
Goodpasture's Syndrome	482	429	36	*	*	0.2	.	0.1	0.1
Post infectious GN, SBE	319	244	54	*	*	0.1	.	0.1	0.2
Glomerulonephritis (GN)	17,832	11,358	4,846	1,235	201	5.3	4.1	9.9	4.1
Other proliferative GN	1,138	829	242	45	12	0.4	0.2	0.4	0.2
Secondary GN/vasculitis	8,569	5,014	3,119	290	96	2.3	2.7	2.3	2.0
Lupus erythematosus (SLE nephritis)	4,068	1,523	2,262	215	34	0.7	1.9	1.7	0.7
Polyarteritis	215	172	28	11	*	0.1	.	0.1	0.1
Wegener's granulomatosis	1,026	930	75	11	*	0.4	0.1	0.1	0.2
Henoch-Schonlein syndrome	148	126	11	*	*	0.1	.	.	0.1
Vasculitis and its derivatives	955	812	98	17	26	0.4	0.1	0.1	0.5
Scleroderma	764	580	165	*	*	0.3	0.1	0.1	0.2
Hemolytic uremic syndrome	710	557	136	*	*	0.3	0.1	0.1	0.1
Nephropathy from heroin /related abuse	285	80	200	*	*	.	0.2	.	.
Secondary GN, other	398	234	144	10	*	0.1	0.1	0.1	0.1
Interstitial nephritis/pyelonephritis	15,002	11,864	2,537	392	100	5.5	2.2	3.1	2.1
Chronic pyelonephritis, reflux neph.	2,195	1,872	227	56	17	0.9	0.2	0.4	0.4
Analgesic abuse	853	661	164	16	*	0.3	0.1	0.1	0.1
Nephropathy caused by other agents	1,953	1,528	373	32	*	0.7	0.3	0.3	0.1
Nephrolithiasis, obstruction, gouty	4,821	3,737	871	150	31	1.7	0.7	1.2	0.6
Nephrocalcinosis	275	223	40	*	*	0.1	.	0.1	.
Chronic interstitial nephritis	4,240	3,292	761	124	33	1.5	0.6	1.0	0.7
Acute interstitial nephritis	665	551	101	*	*	0.3	0.1	0.1	0.1
Hypertensive/large vessel disease	97,455	54,198	39,394	2,899	430	25.3	33.5	23.2	8.9
Hypertension (no primary renal disease)	85,589	43,208	38,716	2,762	392	20.2	32.9	22.1	8.1
Renal artery stenosis or occlusion	7,946	7,283	529	99	21	3.4	0.5	0.8	0.4
Cholesterol emboli, renal emboli	3,920	3,707	149	38	17	1.7	0.1	0.3	0.4
Cystic/hereditary/congenital diseases	12,308	9,934	1,884	289	67	4.6	1.6	2.3	1.4
Polycystic kidneys, adult (dominant)	8,720	7,166	1,251	207	29	3.3	1.1	1.7	0.6
Polycystic, infantile (recessive)	186	146	32	*	.	0.1	.	.	.
Medullary cystic, including nephronophthisis	202	168	23	*	*	0.1	.	.	0.1
Alport's, other hereditary/familial disease	910	771	102	18	11	0.4	0.1	0.1	0.2
Tuberous sclerosis	119	84	28	*	*
Cystinosis	50	45	*
Primary oxalosis	50	42	*
Fabry's disease	65	56	*	.	*
Congenital nephrotic syndrome	213	136	54	14	*	0.1	.	0.1	.
Drash syndrome, mesangial sclerosis	28	21	*	.	*
Congenital obstructive uropathy	1,011	762	201	26	*	0.4	0.2	0.2	0.2
Renal hypoplasia, dysplasia	654	464	152	13	*	0.2	0.1	0.1	0.2
Prune belly syndrome	100	73	24	*
Neoplasms/tumors	7,028	5,400	1,461	98	38	2.5	1.2	0.8	0.8
Renal or urological neoplasms	2,017	1,599	385	20	11	0.7	0.3	0.2	0.2
Multiple myeloma	3,517	2,592	825	60	20	1.2	0.7	0.5	0.4
Light chain nephropathy	445	348	86	*	*	0.2	0.1	0.1	.
Amyloidosis	1,049	861	165	*	*	0.4	0.1	0.1	0.1
Miscellaneous conditions	14,251	8,156	5,765	178	75	3.8	4.9	1.4	1.5
Complication post bone marrow/other txp	383	337	35	*	*	0.2	.	0.1	.
Sickle cell disease/anemia or trait	458	*	445	*	.	.	0.4	.	.
AIDS nephropathy	4,029	209	3,774	*	17	0.1	3.2	.	0.4
Traumatic/surgical loss of kidney(s)	414	340	65	*	*	0.2	0.1	.	.
Hepatorenal syndrome	549	430	89	10	14	0.2	0.1	0.1	0.3
Tubular necrosis (no recovery)	4,727	3,917	701	68	21	1.8	0.6	0.5	0.4
Post-partum failure, other renal disorders	3,691	2,914	656	79	20	1.4	0.6	0.6	0.4
Etiology uncertain	13,997	9,568	3,653	526	118	4.5	3.1	4.2	2.4
Missing	10,040	5,436	3,359	265	59

Table A.15
Incident Counts of Reported ESRD Patients: by Diabetic Status & State
after dropping patients in the U.S. Territories & in states designated as "unknown"

ALL PATIENTS	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
Alabama	885	1,045	1,137	1,121	1,264	1,370	1,476	1,650	1,575	1,675
Alaska	33	51	54	50	199	345	65	80	68	74
Arizona	720	821	996	1,017	1,089	1,183	1,279	1,402	1,539	1,623
Arkansas	394	509	528	568	692	729	713	820	765	801
California	5,450	6,048	6,213	6,623	7,616	7,894	8,330	9,273	9,863	10,264
Colorado	403	468	521	536	555	553	667	712	790	768
Connecticut	597	664	679	681	859	832	874	952	933	908
Delaware	139	174	202	190	223	229	219	219	238	257
District of Columbia	260	309	330	321	289	395	392	419	404	383
Florida	2,903	3,309	3,650	3,664	3,975	4,275	4,746	4,964	5,105	5,215
Georgia	1,427	1,694	1,897	1,879	2,181	2,279	2,449	2,497	2,638	2,826
Hawaii	270	268	291	322	400	384	378	424	437	410
Idaho	137	135	123	135	174	187	203	228	207	247
Illinois	2,283	2,680	2,746	3,095	3,428	3,499	3,552	3,834	4,071	3,796
Indiana	930	1,020	1,169	1,235	1,135	1,548	1,469	1,591	1,783	1,754
Iowa	431	452	525	516	586	532	585	612	665	780
Kansas	403	416	434	416	519	495	560	662	667	671
Kentucky	602	710	780	801	733	945	926	1,034	1,116	1,206
Louisiana	1,033	1,175	1,319	1,321	1,473	1,611	1,586	1,847	2,021	2,148
Maine	148	137	152	164	199	226	210	265	258	240
Maryland	1,059	1,191	1,280	1,323	1,340	1,754	1,839	1,904	2,011	2,022
Massachusetts	905	1,056	1,186	1,242	1,393	1,373	1,474	1,593	1,620	1,382
Michigan	1,733	1,857	2,106	2,211	2,495	2,567	2,851	2,957	3,127	3,185
Minnesota	641	706	765	783	951	837	910	1,007	1,053	1,031
Mississippi	582	654	745	776	944	908	1,004	1,080	1,117	1,175
Missouri	995	1,099	1,162	1,231	1,394	1,440	1,500	1,624	1,783	1,824
Montana	116	142	124	147	147	164	147	146	165	200
Nebraska	218	255	295	272	340	323	351	409	415	469
Nevada	185	247	239	279	350	350	372	398	454	538
New Hampshire	128	146	154	146	180	181	162	196	229	204
New Jersey	1,708	1,933	2,057	2,177	2,469	2,621	2,623	2,905	3,054	3,278
New Mexico	267	344	334	362	361	426	474	494	471	551
New York	3,380	3,630	4,065	4,263	5,157	5,068	5,474	5,901	6,120	6,398
North Carolina	1,396	1,637	1,795	1,936	2,182	2,108	2,389	2,609	2,757	2,736
North Dakota	96	101	123	126	154	115	137	139	133	138
Ohio	1,954	2,123	2,415	2,464	2,516	3,240	3,246	3,418	3,696	3,896
Oklahoma	584	550	664	704	745	786	808	962	1,038	998
Oregon	409	497	483	540	582	577	596	634	658	714
Pennsylvania	2,602	2,728	2,929	2,820	3,609	3,638	3,807	4,138	4,175	4,338
Rhode Island	177	204	204	231	251	229	263	273	301	267
South Carolina	893	962	1,043	1,079	1,332	1,239	1,364	1,452	1,569	1,599
South Dakota	89	98	114	129	141	185	193	195	197	218
Tennessee	979	1,154	1,219	1,172	1,445	1,479	1,518	1,726	1,762	1,944
Texas	3,383	3,731	4,195	4,287	4,726	4,965	5,457	5,814	6,197	6,556
Utah	180	195	197	263	239	264	259	269	344	337
Vermont	66	87	66	73	85	103	99	112	119	118
Virginia	1,194	1,446	1,577	1,562	1,671	1,946	2,059	2,345	2,293	2,344
Washington	681	745	768	807	938	961	989	1,047	1,094	1,249
West Virginia	298	362	381	400	441	492	523	622	636	620
Wisconsin	770	862	954	925	1,056	1,062	1,130	1,226	1,346	1,331
Wyoming	34	43	44	52	42	66	66	69	68	88
All	47,150	52,870	57,429	59,437	67,265	70,978	74,763	81,149	85,145	87,794

Table A.15 (continued)

Incident Counts of Reported ESRD Patients: by Diabetic Status & State*after dropping patients in the U.S. Territories & in states designated as "unknown"*

DIABETICS	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
Alabama	201	310	380	363	459	532	582	722	654	752
Alaska	10	14	17	24	55	120	31	45	31	38
Arizona	290	378	478	476	517	613	621	728	790	831
Arkansas	116	180	175	177	222	279	302	318	294	326
California	1,971	2,290	2,372	2,408	3,019	3,332	3,635	4,260	4,494	4,690
Colorado	162	195	214	241	225	252	328	316	377	355
Connecticut	189	230	234	221	319	322	332	428	373	368
Delaware	44	58	56	60	71	77	81	82	95	115
District of Columbia	82	83	109	85	73	118	158	149	136	146
Florida	857	982	1,123	1,079	1,280	1,312	1,745	1,866	1,901	2,042
Georgia	473	537	643	613	752	894	1,051	1,025	1,106	1,186
Hawaii	140	141	147	183	226	229	231	246	254	222
Idaho	48	40	58	56	76	72	82	103	91	116
Illinois	665	843	822	883	1,162	1,310	1,401	1,460	1,557	1,556
Indiana	326	360	409	374	346	586	627	657	801	751
Iowa	126	144	184	190	212	228	245	253	271	307
Kansas	133	163	147	152	206	186	228	264	314	301
Kentucky	193	239	241	270	228	343	393	443	486	536
Louisiana	329	437	500	429	544	617	693	801	909	947
Maine	39	41	52	58	62	72	72	99	95	96
Maryland	368	423	468	432	454	571	705	780	811	803
Massachusetts	284	342	405	380	501	524	574	605	637	505
Michigan	657	731	825	777	975	1,051	1,260	1,312	1,411	1,381
Minnesota	226	256	273	280	336	325	347	386	396	368
Mississippi	159	225	262	263	332	361	438	437	485	527
Missouri	317	371	419	450	516	574	638	736	781	763
Montana	54	62	66	56	64	85	64	68	83	94
Nebraska	80	99	113	109	127	163	153	175	170	211
Nevada	64	90	79	91	122	158	129	179	204	247
New Hampshire	41	45	43	40	54	69	56	71	85	76
New Jersey	594	664	656	697	876	1,040	1,072	1,169	1,305	1,345
New Mexico	108	188	191	203	193	244	283	277	282	336
New York	1,094	1,210	1,352	1,340	1,644	1,875	2,188	2,382	2,405	2,556
North Carolina	474	585	629	690	848	854	1,020	1,124	1,242	1,179
North Dakota	41	38	60	49	67	51	48	60	64	46
Ohio	665	716	896	882	915	1,277	1,418	1,531	1,688	1,826
Oklahoma	246	241	317	303	331	387	377	458	547	509
Oregon	143	161	175	188	216	226	231	256	248	298
Pennsylvania	858	963	1,043	931	1,272	1,463	1,497	1,648	1,724	1,770
Rhode Island	55	54	66	68	80	85	101	109	122	99
South Carolina	285	344	370	363	485	477	581	597	721	699
South Dakota	29	52	57	61	62	95	92	90	85	114
Tennessee	250	357	421	393	497	588	604	689	698	781
Texas	1,430	1,562	1,736	1,881	2,131	2,374	2,694	3,002	3,145	3,297
Utah	77	84	82	109	111	142	127	131	156	150
Vermont	20	31	17	28	41	50	40	50	49	53
Virginia	359	459	513	523	606	649	795	972	980	967
Washington	236	285	314	305	351	382	409	451	469	525
West Virginia	108	126	156	138	162	204	231	283	276	310
Wisconsin	295	336	376	343	385	438	461	532	547	532
Wyoming	13	13	11	25	22	39	31	35	27	44
All	16,024	18,778	20,752	20,740	24,830	28,315	31,502	34,860	36,872	38,092

Table A.15 (continued)

Incident Counts of Reported ESRD Patients: Diabetic Status by State*after dropping patients in the U.S. Territories & in states designated as "unknown"*

NON-DIABETICS	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
Alabama	684	735	757	758	805	838	894	928	921	923
Alaska	23	37	37	26	144	225	34	35	37	36
Arizona	430	443	518	541	572	570	658	674	749	792
Arkansas	278	329	353	391	470	450	411	502	471	475
California	3,479	3,758	3,841	4,215	4,597	4,562	4,695	5,013	5,369	5,574
Colorado	241	273	307	295	330	301	339	396	413	413
Connecticut	408	434	445	460	540	510	542	524	560	540
Delaware	95	116	146	130	152	152	138	137	143	142
District of Columbia	178	226	221	236	216	277	234	270	268	237
Florida	2,046	2,327	2,527	2,585	2,695	2,963	3,001	3,098	3,204	3,173
Georgia	954	1,157	1,254	1,266	1,429	1,385	1,398	1,472	1,532	1,640
Hawaii	130	127	144	139	174	155	147	178	183	188
Idaho	89	95	65	79	98	115	121	125	116	131
Illinois	1,618	1,837	1,924	2,212	2,266	2,189	2,151	2,374	2,514	2,240
Indiana	604	660	760	861	789	962	842	934	982	1,003
Iowa	305	308	341	326	374	304	340	359	394	473
Kansas	270	253	287	264	313	309	332	398	353	370
Kentucky	409	471	539	531	505	602	533	591	630	670
Louisiana	704	738	819	892	929	994	893	1,046	1,112	1,201
Maine	109	96	100	106	137	154	138	166	163	144
Maryland	691	768	812	891	886	1,183	1,134	1,124	1,200	1,219
Massachusetts	621	714	781	862	892	849	900	988	983	877
Michigan	1,076	1,126	1,281	1,434	1,520	1,516	1,591	1,645	1,716	1,804
Minnesota	415	450	492	503	615	512	563	621	657	663
Mississippi	423	429	483	513	612	547	566	643	632	648
Missouri	678	728	743	781	878	866	862	888	1,002	1,061
Montana	62	80	58	91	83	79	83	78	82	106
Nebraska	138	156	182	163	213	160	198	234	245	258
Nevada	121	157	160	188	228	192	243	219	250	291
New Hampshire	87	101	111	106	126	112	106	125	144	128
New Jersey	1,114	1,269	1,401	1,480	1,593	1,581	1,551	1,736	1,749	1,933
New Mexico	159	156	143	159	168	182	191	217	189	215
New York	2,286	2,420	2,713	2,923	3,513	3,193	3,286	3,519	3,715	3,842
North Carolina	922	1,052	1,166	1,246	1,334	1,254	1,369	1,485	1,515	1,557
North Dakota	55	63	63	77	87	64	89	79	69	92
Ohio	1,289	1,407	1,519	1,582	1,601	1,963	1,828	1,887	2,008	2,070
Oklahoma	338	309	347	401	414	399	431	504	491	489
Oregon	266	336	308	352	366	351	365	378	410	416
Pennsylvania	1,744	1,765	1,886	1,889	2,337	2,175	2,310	2,490	2,451	2,568
Rhode Island	122	150	138	163	171	144	162	164	179	168
South Carolina	608	618	673	716	847	762	783	855	848	900
South Dakota	60	46	57	68	79	90	101	105	112	104
Tennessee	729	797	798	779	948	891	914	1,037	1,064	1,163
Texas	1,953	2,169	2,459	2,406	2,595	2,591	2,763	2,812	3,052	3,259
Utah	103	111	115	154	128	122	132	138	188	187
Vermont	46	56	49	45	44	53	59	62	70	65
Virginia	835	987	1,064	1,039	1,065	1,297	1,264	1,373	1,313	1,377
Washington	445	460	454	502	587	579	580	596	625	724
West Virginia	190	236	225	262	279	288	292	339	360	310
Wisconsin	475	526	578	582	671	624	669	694	799	799
Wyoming	21	30	33	27	20	27	35	34	41	44
All	31,126	34,092	36,677	38,697	42,435	42,663	43,261	46,289	48,273	49,702

Table A.16

Incident Rates of Reported ESRD: by Diabetic Status & State*per million population, adjusted for age, gender, & race*

ALL PATIENTS	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
Alabama	167	199	219	208	242	250	274	291	282	288
Alaska	123	189	178	194	648	1,149	209	289	196	167
Arizona	226	259	299	285	288	304	320	339	359	350
Arkansas	152	203	206	215	258	282	263	296	275	289
California	221	240	239	246	279	280	285	313	337	336
Colorado	158	185	197	193	196	195	219	234	247	237
Connecticut	192	224	229	220	283	266	277	291	288	274
Delaware	207	249	298	246	283	288	266	259	277	293
District of Columbia	159	171	216	195	131	228	210	175	222	204
Florida	201	221	239	236	244	257	288	277	282	277
Georgia	184	219	238	231	262	326	349	276	287	302
Hawaii	172	158	173	217	207	180	173	214	167	177
Idaho	240	182	276	384	336	201	278	378	210	262
Illinois	200	231	238	260	284	284	287	307	321	302
Indiana	192	206	234	254	226	294	286	295	328	320
Iowa	226	229	256	252	305	262	330	261	305	329
Kansas	201	204	208	210	247	232	269	295	297	298
Kentucky	185	217	255	246	218	286	266	288	314	333
Louisiana	208	240	260	257	279	294	284	332	345	395
Maine	141	151	398	145	429	390	335	248	288	207
Maryland	191	211	223	222	219	275	282	295	301	312
Massachusetts	177	201	231	228	264	261	268	282	288	234
Michigan	191	202	224	232	265	265	289	295	311	312
Minnesota	226	230	235	274	317	283	277	287	297	293
Mississippi	168	198	215	217	265	268	273	297	296	319
Missouri	202	221	233	250	275	277	305	303	329	334
Montana	319	324	164	200	325	381	150	146	235	358
Nebraska	180	225	239	251	298	242	290	298	318	355
Nevada	194	224	208	231	286	263	242	247	274	315
New Hampshire	165	220	229	174	224	213	237	191	290	156
New Jersey	213	239	252	262	290	304	298	326	335	357
New Mexico	208	238	232	243	256	275	292	309	264	317
New York	176	189	209	216	250	241	262	281	287	297
North Carolina	177	209	221	233	258	273	305	289	297	285
North Dakota	143	149	187	1,122	475	517	193	336	189	188
Ohio	189	201	227	227	224	291	293	301	322	337
Oklahoma	199	187	219	239	241	251	256	295	318	296
Oregon	169	245	204	241	255	245	248	211	296	275
Pennsylvania	219	225	240	230	297	294	302	321	322	334
Rhode Island	227	228	232	261	303	274	314	308	329	295
South Carolina	205	214	249	234	280	396	456	292	296	295
South Dakota	377	479	360	162	196	241	283	382	395	254
Tennessee	194	225	241	219	266	267	272	302	301	324
Texas	230	251	275	275	294	290	312	328	358	358
Utah	158	174	167	271	212	219	256	219	260	257
Vermont	212	614	218	320	133	459	261	304	318	207
Virginia	180	215	229	224	231	263	275	307	296	297
Washington	187	199	215	214	232	222	232	238	243	260
West Virginia	188	237	233	259	292	325	324	355	351	342
Wisconsin	210	228	253	255	262	275	281	290	319	316
Wyoming	129	298	139	196	144	188	239	217	208	247

Table A.16 (continued)

Incident Rates of Reported ESRD: by Diabetic Status & State*per million population, adjusted for age, gender, & race*

DIABETICS	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
Alabama	34	55	72	65	87	95	107	123	110	125
Alaska	37	39	47	109	217	353	91	189	104	64
Arizona	79	118	142	130	134	157	149	179	180	176
Arkansas	45	71	70	69	85	107	114	115	107	117
California	80	91	91	90	110	118	123	144	154	154
Colorado	63	77	79	82	80	87	110	98	116	110
Connecticut	62	79	82	71	109	104	108	134	120	114
Delaware	66	77	79	77	92	96	98	96	109	129
District of Columbia	33	36	63	31	25	68	88	59	54	64
Florida	63	68	77	72	81	82	108	106	108	109
Georgia	62	72	81	75	90	127	149	113	117	126
Hawaii	90	40	51	64	108	96	91	100	94	85
Idaho	56	42	62	221	73	67	128	165	98	101
Illinois	58	72	71	73	96	106	112	116	122	124
Indiana	65	71	82	78	70	109	120	122	147	136
Iowa	68	77	81	97	116	125	148	131	149	141
Kansas	67	85	72	80	100	91	107	124	141	141
Kentucky	62	72	84	86	68	104	112	123	135	151
Louisiana	67	83	94	84	98	112	120	138	150	173
Maine	28	66	191	40	111	124	120	99	163	65
Maryland	63	73	81	72	75	90	109	120	120	125
Massachusetts	58	66	80	71	97	104	104	110	122	91
Michigan	71	79	88	82	102	109	129	133	142	137
Minnesota	86	84	86	111	112	112	113	125	121	110
Mississippi	54	70	82	69	101	118	119	126	137	146
Missouri	64	76	87	88	101	113	128	138	145	141
Montana	250	181	75	62	105	202	66	69	111	255
Nebraska	65	98	106	115	108	142	123	144	148	178
Nevada	65	74	65	73	95	118	77	109	123	141
New Hampshire	58	43	53	71	66	99	58	59	130	57
New Jersey	73	81	80	83	103	120	121	131	141	144
New Mexico	81	119	122	129	125	147	169	164	151	188
New York	57	62	69	67	81	88	103	112	112	117
North Carolina	61	76	78	84	102	111	129	122	131	121
North Dakota	67	66	98	700	302	307	73	229	97	69
Ohio	64	66	83	82	81	112	126	135	146	156
Oklahoma	78	80	101	97	101	121	116	131	161	145
Oregon	61	77	74	87	104	97	106	90	100	120
Pennsylvania	69	78	86	74	103	119	117	126	132	134
Rhode Island	83	61	83	72	106	105	129	120	144	115
South Carolina	64	79	82	79	106	144	176	115	133	128
South Dakota	38	353	289	80	80	119	115	157	200	136
Tennessee	50	71	84	74	94	106	108	119	117	132
Texas	98	105	114	120	133	139	154	169	182	179
Utah	53	74	73	134	92	138	106	129	153	124
Vermont	32	137	139	232	63	154	119	153	81	78
Virginia	51	65	73	73	83	88	105	125	126	121
Washington	73	85	99	90	84	94	97	107	106	112
West Virginia	70	87	90	85	99	135	145	154	152	185
Wisconsin	83	92	95	96	97	117	123	133	135	137
Wyoming	85	27	32	56	78	84	72	135	85	96

Table A.16 (continued)

Incident Rates of Reported ESRD: by Diabetic Status & State*per million population, adjusted for age, gender, & race*

NON-DIABETICS	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
Alabama	132	144	147	143	154	155	166	168	172	162
Alaska	86	150	130	85	430	796	118	100	92	103
Arizona	147	141	157	155	154	147	171	160	178	174
Arkansas	107	132	137	146	172	175	149	181	168	173
California	140	149	148	156	168	162	161	169	183	182
Colorado	95	109	117	111	116	108	109	135	131	127
Connecticut	130	145	147	148	173	162	170	156	169	160
Delaware	141	171	218	169	190	192	167	163	169	164
District of Columbia	126	136	153	164	106	161	122	116	168	140
Florida	138	153	161	164	163	175	180	171	174	168
Georgia	122	146	157	155	172	199	200	163	170	176
Hawaii	82	118	122	153	98	84	82	114	74	91
Idaho	184	140	214	162	263	134	150	213	112	161
Illinois	141	159	167	187	187	178	175	191	198	179
Indiana	127	134	152	175	156	185	166	174	182	184
Iowa	158	151	175	154	189	137	181	131	156	189
Kansas	134	119	136	130	146	142	162	171	155	158
Kentucky	122	145	171	161	150	181	154	166	179	182
Louisiana	141	157	166	173	181	182	164	194	194	222
Maine	113	85	207	106	318	266	216	149	125	142
Maryland	128	138	142	150	144	185	174	174	181	187
Massachusetts	120	135	151	157	167	157	164	172	166	143
Michigan	120	123	137	150	162	156	160	162	170	175
Minnesota	139	145	149	163	205	171	164	162	176	183
Mississippi	115	129	133	149	164	150	154	170	160	173
Missouri	137	145	146	162	173	164	177	165	183	194
Montana	69	144	89	138	220	179	84	78	125	104
Nebraska	116	127	133	137	190	100	167	154	169	177
Nevada	128	150	142	159	191	145	165	138	151	174
New Hampshire	107	178	177	103	158	114	178	132	160	98
New Jersey	139	158	173	178	187	183	178	195	193	212
New Mexico	127	120	110	114	131	128	123	144	114	128
New York	120	127	140	149	169	153	158	169	174	180
North Carolina	116	133	143	149	156	162	176	168	166	164
North Dakota	76	84	89	421	172	210	121	107	92	119
Ohio	124	135	144	145	143	179	167	166	175	181
Oklahoma	121	107	118	142	140	130	140	164	157	151
Oregon	109	168	129	154	151	148	142	121	197	155
Pennsylvania	150	147	155	156	194	176	184	195	190	199
Rhode Island	144	168	150	190	196	168	184	189	185	180
South Carolina	142	135	167	155	174	251	280	177	163	167
South Dakota	339	125	71	82	116	122	169	226	195	118
Tennessee	144	154	157	145	172	161	164	182	184	192
Texas	132	146	161	155	161	151	158	159	176	179
Utah	105	100	94	137	120	81	150	91	107	133
Vermont	181	477	79	88	70	304	142	151	237	129
Virginia	129	150	156	151	148	175	170	182	170	176
Washington	113	114	117	124	148	128	136	131	137	148
West Virginia	118	151	143	174	193	190	179	201	199	158
Wisconsin	127	136	159	158	165	158	158	157	184	178
Wyoming	44	271	108	140	65	103	167	81	123	152

Table A.17

Incident Counts of Reported ESRD Patients: by Diabetic Status & Network

after dropping patients in the U.S. Territories & in states designated as "unknown"

ALL PATIENTS	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
1 CT, MA, ME, NH, RI, VT	2,023	2,293	2,442	2,538	2,968	2,963	3,082	3,388	3,460	3,122
2 NY	3,380	3,629	4,078	4,265	5,268	5,133	5,475	5,903	6,120	6,395
3 NJ, PR	1,708	1,934	2,052	2,176	2,478	2,639	2,616	2,904	3,052	3,274
4 DE, PA	2,742	2,907	3,138	3,010	3,794	3,745	4,031	4,359	4,413	4,598
5 MD, DC, VA, WV	2,809	3,309	3,563	3,602	3,729	4,594	4,814	5,292	5,347	5,371
6 NC, SC, GA	3,715	4,291	4,731	4,892	5,693	5,635	6,205	6,557	6,964	7,161
7 FL	2,903	3,307	3,649	3,664	3,950	4,268	4,748	4,967	5,107	5,215
8 AL, MS, TN	2,446	2,854	3,099	3,071	3,650	3,771	3,997	4,454	4,456	4,795
9 IN, KY, OH	3,486	3,852	4,365	4,495	4,391	5,750	5,634	6,045	6,596	6,857
10 IL	2,283	2,677	2,747	3,102	3,484	3,532	3,555	3,830	4,067	3,792
11 MI, MN, ND, SD, WI	3,331	3,626	4,061	4,181	4,828	4,807	5,228	5,526	5,860	5,906
12 IA, KS, MO, NE	2,048	2,223	2,419	2,436	2,836	2,798	2,997	3,307	3,532	3,745
13 AR, LA, OK	2,012	2,234	2,512	2,591	2,922	3,138	3,106	3,630	3,823	3,946
14 TX	3,382	3,732	4,196	4,290	4,637	5,002	5,456	5,816	6,199	6,555
15 AZ, CO, NV, NM, UT, WY	1,787	2,117	2,331	2,512	2,660	2,868	3,114	3,344	3,666	3,906
16 AK, ID, MT, OR, WA	1,373	1,573	1,542	1,666	1,923	1,964	2,001	2,135	2,190	2,484
17 N. CA, HI, GUAM, AS	2,375	2,544	2,608	2,782	3,173	3,283	3,484	3,865	3,947	4,098
18 S. CA	3,347	3,768	3,896	4,164	4,881	5,088	5,220	5,827	6,346	6,574
All	47,150	52,870	57,429	59,437	67,265	70,978	74,763	81,149	85,145	87,794
DIABETICS										
1 CT, MA, ME, NH, RI, VT	628	742	817	797	1,059	1,126	1,175	1,362	1,361	1,197
2 NY	1,094	1,210	1,356	1,341	1,662	1,882	2,189	2,382	2,405	2,556
3 NJ, PR	594	665	655	698	878	1,050	1,071	1,169	1,305	1,345
4 DE, PA	902	1,020	1,100	988	1,328	1,477	1,577	1,730	1,819	1,885
5 MD, DC, VA, WV	917	1,091	1,245	1,177	1,290	1,545	1,890	2,184	2,203	2,226
6 NC, SC, GA	1,231	1,466	1,641	1,667	2,088	2,228	2,652	2,746	3,069	3,064
7 FL	857	982	1,123	1,079	1,272	1,309	1,745	1,866	1,902	2,042
8 AL, MS, TN	610	892	1,063	1,018	1,290	1,485	1,624	1,846	1,837	2,061
9 IN, KY, OH	1,184	1,316	1,543	1,525	1,501	2,214	2,435	2,633	2,974	3,113
10 IL	666	842	821	885	1,176	1,326	1,403	1,459	1,558	1,555
11 MI, MN, ND, SD, WI	1,248	1,414	1,591	1,511	1,831	1,977	2,214	2,379	2,504	2,442
12 IA, KS, MO, NE	656	777	863	902	1,057	1,150	1,265	1,428	1,536	1,583
13 AR, LA, OK	691	858	992	909	1,101	1,290	1,372	1,577	1,749	1,782
14 TX	1,430	1,561	1,736	1,881	2,096	2,390	2,694	3,004	3,147	3,296
15 AZ, CO, NV, NM, UT, WY	714	948	1,056	1,146	1,204	1,463	1,517	1,666	1,836	1,964
16 AK, ID, MT, OR, WA	491	564	630	622	734	804	818	923	921	1,071
17 N. CA, HI, GUAM, AS	881	935	1,006	1,076	1,330	1,439	1,585	1,794	1,837	1,810
18 S. CA	1,230	1,495	1,514	1,518	1,933	2,160	2,276	2,712	2,909	3,100
All	16,024	18,778	20,752	20,740	24,830	28,315	31,502	34,860	36,872	38,092
NON-DIABETICS										
1 CT, MA, ME, NH, RI, VT	1,395	1,551	1,625	1,741	1,909	1,837	1,907	2,026	2,099	1,925
2 NY	2,286	2,419	2,722	2,924	3,606	3,251	3,286	3,521	3,715	3,839
3 NJ, PR	1,114	1,269	1,397	1,478	1,600	1,589	1,545	1,735	1,747	1,929
4 DE, PA	1,840	1,887	2,038	2,022	2,466	2,268	2,454	2,629	2,594	2,713
5 MD, DC, VA, WV	1,892	2,218	2,318	2,425	2,439	3,049	2,924	3,108	3,144	3,145
6 NC, SC, GA	2,484	2,825	3,090	3,225	3,605	3,407	3,553	3,811	3,895	4,097
7 FL	2,046	2,325	2,526	2,585	2,678	2,959	3,003	3,101	3,205	3,173
8 AL, MS, TN	1,836	1,962	2,036	2,053	2,360	2,286	2,373	2,608	2,619	2,734
9 IN, KY, OH	2,302	2,536	2,822	2,970	2,890	3,536	3,199	3,412	3,622	3,744
10 IL	1,617	1,835	1,926	2,217	2,308	2,206	2,152	2,371	2,509	2,237
11 MI, MN, ND, SD, WI	2,083	2,212	2,470	2,670	2,997	2,830	3,014	3,147	3,356	3,464
12 IA, KS, MO, NE	1,392	1,446	1,556	1,534	1,779	1,648	1,732	1,879	1,996	2,162
13 AR, LA, OK	1,321	1,376	1,520	1,682	1,821	1,848	1,734	2,053	2,074	2,164
14 TX	1,952	2,171	2,460	2,409	2,541	2,612	2,762	2,812	3,052	3,259
15 AZ, CO, NV, NM, UT, WY	1,073	1,169	1,275	1,366	1,456	1,405	1,597	1,678	1,830	1,942
16 AK, ID, MT, OR, WA	882	1,009	912	1,044	1,189	1,160	1,183	1,212	1,269	1,413
17 N. CA, HI, GUAM, AS	1,494	1,609	1,602	1,706	1,843	1,844	1,899	2,071	2,110	2,288
18 S. CA	2,117	2,273	2,382	2,646	2,948	2,928	2,944	3,115	3,437	3,474
All	31,126	34,092	36,677	38,697	42,435	42,663	43,261	46,289	48,273	49,702

On our website: incident rates by network before dropping patients in Territories and "unknown" states (Table A.I).

Table A.18

Incident Rates of Reported ESRD: by Diabetic Status & Network*per million population, adjusted for age, gender, & race*

ALL PATIENTS	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
1 CT, MA, ME, NH, RI, VT	186	210	222	225	268	266	269	285	293	256
2 NY	179	190	212	219	255	244	264	285	290	302
3 NJ, PR	215	243	255	268	295	310	304	334	342	365
4 DE, PA	218	228	244	234	292	287	302	325	325	335
5 MD, DC, VA, WV	186	216	228	227	230	275	286	314	314	315
6 NC, SC, GA	184	207	225	227	259	234	249	283	292	296
7 FL	203	220	237	233	245	258	290	283	286	282
8 AL, MS, TN	179	210	223	217	251	252	270	296	291	312
9 IN, KY, OH	189	207	233	237	228	298	287	303	327	338
10 IL	203	234	233	262	289	291	289	311	328	309
11 MI, MN, ND, SD, WI	191	206	225	232	261	258	278	287	300	300
12 IA, KS, MO, NE	199	213	228	233	267	254	273	290	316	328
13 AR, LA, OK	187	209	229	233	260	273	265	309	317	328
14 TX	234	253	280	277	292	297	317	333	326	366
15 AZ, CO, NV, NM, UT, WY	180	208	220	226	237	244	246	262	276	285
16 AK, ID, MT, OR, WA	178	211	206	222	232	222	231	232	248	253
17 N. CA, HI, GUAM, AS	219	234	230	238	255	256	263	299	302	297
18 S. CA	223	246	247	251	294	299	298	324	360	359
DIABETICS	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
1 CT, MA, ME, NH, RI, VT	62	71	77	71	99	104	105	118	124	103
2 NY	57	63	69	68	82	88	104	113	113	118
3 NJ, PR	73	84	81	85	105	124	124	135	144	148
4 DE, PA	71	78	84	75	101	113	117	128	134	137
5 MD, DC, VA, WV	59	70	80	73	80	93	113	130	129	131
6 NC, SC, GA	61	68	77	77	94	91	104	116	124	124
7 FL	63	69	76	72	82	81	107	109	109	112
8 AL, MS, TN	44	64	75	71	87	97	108	120	117	132
9 IN, KY, OH	64	70	81	79	77	113	123	131	147	152
10 IL	59	73	71	75	98	108	113	118	125	126
11 MI, MN, ND, SD, WI	70	79	86	82	97	103	116	122	127	123
12 IA, KS, MO, NE	65	77	83	86	101	106	115	129	139	141
13 AR, LA, OK	61	77	86	79	94	107	112	128	139	142
14 TX	99	106	116	122	133	142	157	173	166	183
15 AZ, CO, NV, NM, UT, WY	63	83	91	92	98	116	108	122	130	134
16 AK, ID, MT, OR, WA	69	80	90	90	86	93	95	105	101	107
17 N. CA, HI, GUAM, AS	80	82	86	88	102	106	112	133	136	126
18 S. CA	82	98	95	92	117	128	130	152	166	171
NON-DIABETICS	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
1 CT, MA, ME, NH, RI, VT	124	139	145	154	169	162	163	166	169	153
2 NY	122	127	143	151	173	156	160	172	176	183
3 NJ, PR	142	160	174	182	191	186	181	199	198	217
4 DE, PA	148	150	160	158	191	174	184	197	192	198
5 MD, DC, VA, WV	127	146	148	154	150	181	173	184	185	184
6 NC, SC, GA	123	139	147	150	164	144	145	168	168	172
7 FL	140	151	161	161	162	177	183	174	177	171
8 AL, MS, TN	135	145	148	145	164	155	162	176	174	180
9 IN, KY, OH	125	137	152	158	151	185	164	172	180	186
10 IL	144	161	162	188	190	182	177	193	203	182
11 MI, MN, ND, SD, WI	121	127	139	150	164	155	162	164	173	177
12 IA, KS, MO, NE	134	136	145	147	167	148	158	161	177	187
13 AR, LA, OK	126	133	143	154	166	166	153	181	179	186
14 TX	134	147	164	155	159	155	161	161	160	183
15 AZ, CO, NV, NM, UT, WY	117	125	130	133	139	128	138	140	146	151
16 AK, ID, MT, OR, WA	109	132	116	132	146	129	136	127	147	145
17 N. CA, HI, GUAM, AS	140	152	144	150	154	150	151	166	166	171
18 S. CA	141	148	151	159	177	172	167	172	194	188

A